CURRICULUM VITAE
CHAWNSHANG CHANG; (U.S.A. Citizen) Name & Citizenship:
Date & Place of Birth: November 26, 1955. Taiwan.
Office Address: 601 Elmwood Ave. Box 626, University of Rochester, Rochester, NY 14642
(Tel:585-2759994; Fax:585-7564133; E-Mail: chang@urmc.rochester.edu)
Education:
1974-1978
1978-1980
1980-1985
1985-1988
National Taiwan University (B.S.)
Army Chemical School (R.O.T.C.)
University of Chicago (Ph.D.)
University of Chicago (Post Dr.)
Agriculture Chemistry
Nuclear Chemistry & Biology
Biochemistry & Molecular Biology
Molecular Endocrinology
Academic Experience:
1988-90 Assistant Professor and Director, Urology Research Labs, Dept. of Surgery/Urology and Ben May Institute for Cancer Research, University of Chicago, Chicago, IL
1990-00 Assistant Professor (90-93), Associate Professor (93-96), Professor (96-97). Visiting
Professor (97-00), Director, Tissue & Blood Bank (90-97). Departments of Human
Oncology and Medicine and UW Comprehensive Cancer Center, UW-Madison, WI
1998- Visiting Professor, Osaka University, Yokohama University, Japan; Peking
University and Xiamen Univ. ,Wuhan Univ., Tianjin Medical Univ, China
1999- Visiting Prof., Chang Gung Univ./National Taiwan Univ./Taipei Medical Univ.
1997-02 Director, Molecular Oncology Graduate Program. Univ. of Rochester, Rochester,
NY
1997- Director, George Whipple Laboratory for Cancer Research, Univ. of Rochester,
1997- Director, Urology Research Center, University of Rochester, Rochester, NY
George Whipple Distinguished Professor, Departments of Pathology, Urology and
Radiation Oncology, and The Cancer Center, University of Rochester, Rochester, NY
2000Founder, AndroScience Corporation. San Diego, CA.
Honors:
1988 The Ayerst Award for Outstanding Young Endocrinologist from the Endocrine
Society
1989 Andrew Melon Award for Outstanding Young Faculty in USA from Andrew Melon
Foundation
1990 Outstanding Young Investigator Award from Cancer Research Foundation
2003 The Milheim Award for Excellence in Cancer Research from Milheim Foundation
1992 Tokyo Society of Medical Science and University of Tokyo Lecturer
1991-94 American Cancer Society Junior Professorship in Cancer Research
1995-97 Blowity-Ridgeway Award in Andrology from Blowity-Ridgeway Foundation
1991-97 CapCure Award (6 times) for Excellence in Prostate Cancer Research
1996 Award with Honorary Fellow from The Japan Society of Andrology (The 2nd Non-
Japanese ever awarded such honor)
1998 Scholar of the Year, The highest honor from The Taiwanese Osteoporosis
Association for Outstanding Contribution in Sex hormones and Osteoporosis.
1998 George Hoyt Whipple Lecture, University of Rochester, Rochester, NY
1998 Jieping Wu Award, for Outstanding Achievement in Urology (The highest honor for
Chinese-Urology Researcher). Beijing, China.
1

1999 President Award for Outstanding Urology Research, The highest honor from The
Urology Association of Taiwan for the Contribution in Androgen Receptor and
Prostate Cancer.
1999 Davey Memorial Award for Outstanding Cancer Research, University of Rochester.
2000 President Award for Outstanding Andrology Research, The highest honor from The
Taiwanese Andrology Association for the studies of Androgens and Androgen
Receptor.
2001
Who’s Who in America
2001 Dr. S.T.Huang-Chan memorial Lecture/Award, University of Hong Kong.
2001 President Award for Outstanding Andrology Research, The highest honor from The
Chinese Andrology Association for the studies of Androgens and Androgen Receptor.
2002 Dr. Chien-Tien Hsu Memorial Lecture/Award at 2002 Annual Meeting of OBGYN
2007 DOD Jackson Lecture at Uniform University.
2008 Frontier Oncology Lecture at University of Maryland
Grant and Publication Review:
1.Member of Editorial Board, Endocrine (2000-)
2.Member of Editorial Board, The Prostate Journal (2002)
3.Member of Editorial Board, The Prostate (2003)
4.Member of Editorial Board, Neuroimmune biology (2002)
5.Reviewer in PNAS/JBC/Mol Endo/Cancer Research and 16 other peer-reviewed journals
6.NIH Study Section: Ad Hoc & Regular Member at Biochemical Endocrinology & Other
Study Sections (1995-2001)
7.NIH Study Section: Ad Hoc & Regular Member at Reproductive Endocrinology (2003)
8.VA Merit Grant Oncology Study Section (1996-2002)
9.NIH Prostate SPORE P50 Center Grant; and NIH PO1 Core Grant, NIH Research Centers in
Minority Institutes Core Grant, NIH P19 Orphan Receptor Center Grant.
10.ARMY Breast and Prostate Cancer Grant Study Section (1999-)
11.Air Force TCDD Grant (reviewer) (2001)
12.Medical Research Council of Canada and Dutch Cancer Society Grant;
13.Taiwan CRC Biomedical Sciences Project and Taiwan National Science Council Grant
14.Hong Kong Earmarked Research Grant; Italian Association for Cancer Research
Mentorship/Teaching:
Over 108 Ph.D students/PostDrs. were trained in Chang’s Lab since 1988.
Current Research Grants: direct cost only (55% extra indirect cost for U of R)
NIH Grants:
2007-2012 R01 Grant CA127300, Years 1-5 ($950,000), P.I.
Title: New Mice Models for Studies of Androgen Receptor in Prostate Cancer
2007-2012 R01 Grant CA122840, Years 1-5 ($950,000), P.I.
Title: Loss of Androgen Receptor Promotes Metastatic Cancer
2007-2012 R01 Grant CA122295, Years 1-5 ($950,000), P.I.
Title: Androgen Receptor Roles in Liver Cancer Incidence and Progression
2007-2010 R01 Grant DK73414, Years 1-4 ($780,000), P.I.
Title: Androgen Receptor in B cell Development and Functions
Non-NIH Grants:
1997-2022 George Whipple Professorship Endowment for 25 years
2

Previous Research Grants: direct cost only (59% extra indirect cost for U of R)
NIH Grants:
2003-2006 RO1 Grant DK067686, Year 1-3 ($528,000), P.I.
Title: Androgen Receptor in Prostate Cancer and Bone
2003-2007 RO1 Grant DK063212, Year 1-4 ($940,000), P.I.
Title: Single and Double Knockout of TR2 and TR4 Receptors
2002-2007 RO1 Grant DK060948, Year 1-5 ($871,000), P.I.
Title: Suppression of Androgen Receptor by PTEN
2001-2005 RO1 Grant DK060905, Year 1-4 ($700,000), P.I.
Title: Induction of AR Transactivation by DHT and E2
2001-2004 RO1 Grant DK056984, Year 1-3 ($700,000), P.I.
Title: TR4 ORPHAN RECEPTOR IN TESTIS
1998-2000 NIH-NCI Research Grant Contract, Year 1-3 ($180,000), P.I.
Title: ARA-A1B1 CAG repeat polymorphism
1997-2000 RO1 Grant CA077532, Year 1-3 ($806,592), P.I.
Title: AR-ASSOCIATED PROTEINS IN PROSTATE CARCINOGENESIS
1997-2001 RO1 Grant CA055639-01 Year 6-8, P.I.
Title: T vs DHT specific antiandrogens in prostate cancer.
1995-2000 RO1rant DK051346, Year 1-5 ($950,815), P.I.
Title: MOLECULAR EPIDEMIOLOGY OF AR EXPRESSION IN PROSTATE
1995-1999 RO1 Grant DK047258, Year 1-4 ($1,517,400), P.I.
Title: TR2 AND TR3 ORPHAN RECEPTORS IN PROSTATE CANCER
1994-1998 P30 Grant CA014520, Year 1-4, P.I.
Title: CORE--SAMPLE AND TISSUE ACQUISITION
1992-1997 R29 Grant CA055639, Year 1-5 ($569,343), P.I.
Title: ANDROGEN RECEPTORS IN THE TFM SYNDROME
1998-2000
NIH Training Grant ($60,000 for Drs. Young & Yeh to study in P.I.’ lab)
1995-1998 NIH Research Grant CA 23563 ($465,433) Co P.I. (P.I.:Verma)
1993-1997 NIH Research Grant P30 CA 14520 ($210,000), P.I. (Tissue Bank Project)
1993-1994 NIH Training Grant ($40,000 for Dr. Lin to study in my lab)
1992-1997 NIH Research Grant CA 10536 ($607,331) Co P.I. (P.I.:Weindruch)
1990-1997 NIH Research P30 CA 14520. Co Investigator, 30% salary support
Non-NIH Grants:
2007-2007 Kennedy’s Disease Association grant, Year 1($25,000), P.I.
Title: New therapy for SBMA
2004-2007 ARMY Grant, Years 1-3 ($375,000), P.I.
Title: Knockout AR in Prostate
2002-2004 ARMY Research Grant ($300,000), P.I.
Title: PTEN in breast cancer.
2001-2004 ARMY Prostate Research Grant ($375,000), P.I.
Title: suppression of AKT signal in prostate cancer.
1999-2002 CaP CURE Research Award ($600,000), P.I.
Title: The roles of AR in prostate
1998-2001 ARMY Prostate Research Grant ($486,000), Co-P.I. (PI:Harrison.
Title: Androgen effects on LNCaP prostate cancer cell growth
1997-2001 Rhone-Poulenc Rorer Research Award ($50,000)
3

Title: AR Coregulators
1996-1997 The Blowity-Ridgeway Foundation Award ($120,000), P.I.
1996-1997 Glaxo Research Fund ($35,000), P.I.
1995-1997 Hollis-Eden Research Award ($60,000).
Title: DHEA-derivatives receptor.
1995-1996 UW Comprehensive Cancer Center Award ($14,000), P.I.
1995-1996 UW Graduate School Research Award ($10,000), P.I.
1994-1996 Triton Research Fund ($21,400), P.I.
1994-1996 UW Medical School Merit Award ($65,000), P.I.
1994-1996 Anderson Research Fund ($23,000), P.I.
1994-1995 CaP CURE Research Award ($100,000), Co P.I. (P.I.:Messing)
1994-1995 Adria Research Fund ($20,000), P.I.
1992-1997 Taiwan National Science Council ($100,000 for 2 scientists studying in lab )
1992-1994 Uehara Foundation ($20,000 for Dr. Kurada to study in my lab)
1992-1994 Shiseido Research Foundation ($35,000), P.I.
1991-1994 ACS Research Grant BE-78 and BE-78a ($314,968), P.I.
1991-1994 University of Wisconsin Grants (4 grants for total $106,000), P.I.
1990-1993 American Cancer Society Junior Faculty Award ($90,500)
1989-1991 Cancer Research Foundation Young Investigator Award ($40,000)
1989-1991 Milheim Foundation Young Investigator Award ($20,000)
1988-1991 American Cancer Society (ACS) Research Grants ($81,415), P.I.
1988-1989 Louis Block and Coleman Foundations ($45,000), P.I.
Patents:
1. Androgen receptor and TR2 orphan receptor.
2. Androgen receptor coregulators ARA70, ARA55, ARA54, ARA24, BRCA1, Rb
3. Using differential length of androgen receptor’ and ARAs’ CAG repeat to predict prostate cancer risk in Chinese population.
4.Cross-talk between androgen receptor
IL6/PI3K/AKT, PTEN, BRCA1, RB).
5.Using Aortic endothelial cells to screen SERMs.
6.Vitamin E as anti-prostate cancer agent
7.Androgen receptor knockout mice
8.TR2 and TR4 knock out mice
9. Antiandrogen HF activates MAPK pathway in prostate cancer.
10.Cucurmin analogs function as antiandrogen
Invited Speaker:
I. International and National Meetings: (Total 96 since 1988)
1 .
Second International Symposium on "The Steroid/Thyroid Hormone Receptor Family and Gene Regulation", Stockholm, Sweden. (1988)
2.Satellite Symposium of the 8th International Congress of Endocrinology on "Steroid
Antagonists", Kyoto, Japan. (1988)
3.Prostate Cancer National Symposia on "Molecular and Cellular Biology of Prostate
Cancer", Prouts Neck, Maine. (1989)
4.Terra Symposia on "Androgens & Antiandrogens", New Paltz, New York. (1991)
4

5.The First International Symposium on "Steroid Receptor Superfamily", UW-Madison. WI
(1992) Symposium director.
6.First Asian & Oceanic Congress of Andrology, Nanjing, China (1992).
7.International Symposium on Tumor Biology, Taipei, Taiwan (1994)
8.International Symposium on Sex Hormones and Antihormones, Milano, Italy (1994)
Chairman of the Androgen Section.
9.American Urological Association Summer Research Conference, Houston, Texas (1994)
10.The American Association for Cancer Research/Taiwan Conference, Taipei, Taiwan (1994)
11.The Second International Symposium on "Steroid Receptor Superfamily", UW-Madison. WI
(1994) Symposium director.
12.The Second International Conference on Androgens, Long Beach, CA (1995)
13.Mary Lasker Symposium on Frontiers of Cancer Research, San Diego, CA (1995)
14.The Second Annual CaP CURE Scientific Meeting, Santa Barbara, CA (1995)
15.The Second Symposium of Severtance Institute of Andrology, Seoul, Korea (1996)
16.The Third Annual CaP CURE Scientific Meeting, Lake Tahoe, CA (1996)
17.The 10th International Congress of Endocrinology, SF, CA (1996)
18.National Prostate Cancer Coalition, Houston, TX (1996)
19.The Third International Symposium on "Steroid Receptor Superfamily", UW-Madison. WI
(1996), Symposium director.
20.The Fourth Annual CaP CURE Scientific Meeting, Lake Tahoe, CA (1997)
21.Golden Conference. New England (1997)
22.The VIth International Congress of Andrology, Salzburg, Austria (1997), Plenary Lecture
23.Cambridge Symposium on “Gene Transcription and Therapeutic Interaction”. Washington
D.C. (1997)
24.The 7th SCBA International Symposium on Hormone Action, Toronto, Canada (1997)
25.International Symposium of “Molecular Basis of Sex Hormone Receptor Function-New
Targets for Intervention”, Berlin, Germany (1997)
26.The International Symposium for 50th Year Urology in Yokohama City University, Japan.
(1997), Keynote speaker.
27.The Japan Annual Andrology Meeting, Yokohama, Japan. (1997), Keynote speaker
28.The China Andrology Meeting, Yichong. China (1997), Keynote speaker.
29.The Annual Endocrine Society Meeting, Minneapolis, (1997)
30.The Fifth Annual CaP CURE Scientific Meeting, Lake Tahoe, CA (1998)
31.The China-Japan International Urology Symposium, Shanghai, China, Keynote speaker (1998)
32.The Annual China Urology Meeting, Shanghai, China, Keynote speaker (1998)
33.Keystone Symposium on “Nuclear Receptor Gene Family”, (1998)
34.The First International Chinese Urology Symposium, Shanghai, China, Keynote speaker (1998)
35.The Annual Taiwan Urology Meeting, Hualein, Taiwan, Keynote speaker (1999)
36.AACR Conference on “The Steroid Receptor Superfamily”, Palm Springs, CA (1999)
37.The 8th SCBA International Symposium on Hormone Action, Hong Hong (1999)
38.The Annual Taiwanese Osteoporosis Association Meeting, Kaohsiung, Taiwan,
Keynote speaker (1999)
39.International Conferences on Gene Therapy and Mol. Biology & Medicine, Crete, Greece (1999)
40.The Sixth Annual CaP CURE Scientific Meeting, Lake Tahoe, CA (1999)
41.The Annual Endocrine Society Meeting, San Diego, (1999)
42.The 92nd Annual Meeting of Formosan Medical Association, Taipei, (1999)
43.Golden Conference, New England (1999)
44.North American Taiwanese Professor Association, Irvine, CA (1999)
45.The Asia-Pacific International Urology Meeting. Beijing, China, Keynote speaker (2000)
5

46.17
th Meeting of the International Academy of Tumor Marker Oncology, Hong Kong (2000)
47.The Second International Chinese Urology Symposium. Beijing, China, Keynote speaker (2000)
48.The Annual China Urology Meeting, Beijing, China, Keynote speaker (2000)
49.The 4 th International Spinal and Muscular Atrophy Research & Clinical Meeting, St Louis (2000)
50.The Steroid Receptors and Cell Signal Pathways Symposium, Cincinnati, Ohio (2000)
51.The International Scientific Summit Conference On Current Gynecology, Taipei, Taiwan (2000)
52.The Annual Chinese Andrology Meeting, Han-Chou, China, Keynote speaker (2001)
53.The Annual Taiwanese Andrology Meeting, Taichung, Taiwan. Keynote speaker (2001)
54.US-Taiwan Global Bio/Pharm Conference, Newark, NJ (2001)
55.Annual Meeting of Taiwanese Association of OBGYN, Taipei, Taiwan (2002)
56.The 2002 Annual Meeting of Chinese Medical Association, Taipei, Taiwan (2002)
57.The 2002 Annual Meeting of Taiwanese Urology Association, Taipei, Taiwan (2002)
58.the 3 rd Conference of the Pacific Rim Society for Fertility and Sterility, Taipei, Taiwan (2002)
59.The 2002 Annual Meeting of Chinese Urology Association, Changsha, China (2002)
60.The 12 th Asia-Oceania Congress of Endocrinology, Taipei, Taiwan (2002)
61.Midwest Taiwanese Summer Conference, Bowling Green, Ohio (2003)
62.Asia-Pacific Conference of Aging Male Study, Taipei, Taiwan (2003)
63.Jensen Symposium on Nuclear receptors and Endocrine Disorders, Cincinnati, Ohio (2003)
64.Taiwan Biotechnology Symposium, Chan-Wha, taiwan (2003)
65.10
th SCBA International Synposium, Beijing, China. (2004)
66.Symposium on Anti-tumor Drug Discovery-from basic to clinical”, Taipei, Taiwan (2003)
67.The 6 th US-Taiwan Neuroscience Symposium, New Orleans (2003)
68.Sex Hormones and Endocrine Disorders International Symposium, Kaohsiung, Taiwan (2004)
69.SCBA Meeting, Beijing (2004)
70.Japan Andrology Annual Meeting, Yokohama, Japan (2004)
71.SBUR Fall Symposium, Savannah, GA (2004)
72.AUA Annual Meeting, Atlanta, GA (2006)
73.World Chinese Urology Meeting, Atlanta, GA (2006)
74.Pacific-Asia Andrology Symposium, Shanghai, China (2006)
75.The 10 th Biomedical Material and Technology Symposium, Taipei, Taiwan (2006)
76.Endocrine Society Annual Meeting, Boston, MA (2006)
77.China Urology Association Annual Meeting, Shenyang, China (2006)
78.3
rd Scientific Meeting of the Asian-Pacific Menopause Federation, Taipei, Taiwan (2007)
78.2007 American Physiological Society Conference, Austin, TX (2007)
79.CRC Hormone & Cancer Golden Conference, New London, NM (2007)
80.International Prostate Cancer Conference, Changchun, China (2007)
81.Zer-Jiang Andrology Meeting, HangZhou, China, (2007)
82.Taiwan Medical Association Annual Meeting, Taipei, Taiwan (2007)
83.Department of Defense Annual Prostate Meeting, Atlanta, GA (2007)
84.Taiwan Association of Urology Annual Meeting, Taichung, Taiwan (2007)
85.China Association of urology Annual Meeting, Xiamen, China (2007)
86.Prostate Cancer Foundation, Lake Tahao, NV (2007)
87.13
th World Congress of Gynecological Endocrinology, Pisa, Italy (2008)
88.2
nd International Forum on the Progressing Urology, Tianjin, China (2008)
89.Chinese Urology Association Annual Meeting, Kunmin, China (2008)
90.Taiwanese Andrology Annual Meeting, Taipei, Taiwan (2008)
91.3
rd Greatwall International Andrology Forum, Guilin, China (2008)
92.International Symposium for Institute of Urology-Peking University, Beijing (2008)
93.2008 Kennedy’s Disease Conference, Baltimore, MA (2008)
6

94.SBUR Fall Symposium, Phoenix, AZ (2008)
95.97
th Japan Urology Association Annual Meeting, Okayama, Japan (2009)
96.3
rd Asia-Pacific Forum on Andrology, Nanjing, China (2009)
97.Cnina Urology Association Annual Meeting, Chen-Dou, China (2009)
98.International Tumor Metastasis Symposium, Tienjing, China (2009)
1. McGill University, Department of Pediatrics, Montreal, Canada. (1988)
2. Institute of Biological Chemistry Academia Sinica, Taiwan. (1988)
3. Baylor College of Medicine, Department of Cell Biology, Houston, Texas. (1988)
4. Georgetown University, Department of Anatomy and Cell Biology, Washington DC. (1988)
5. M.D. Anderson Hospital and Tumor Institute, Section of Urology, Houston, Texas. (1988)
6. National Taiwan University, Department of Biological Chemistry, Taiwan. (1988)
7. University of Chicago, Department of Medicine, Chicago, Illinois. (1988)
8. Columbia University, Department of Urology, New York, New York. (1988)
9. Mt. Sinai Medical School, Department of Urology, New York, New York. (1988)
10.Karolinska Institutet, Department of Medical Nutrition, Stockholm, Sweden. (1988)
11.Case Western Reserve University, Department of Biochemistry, Cleveland, Ohio. (1989)
12.University of Tokyo, Department of Zoology, Tokyo, Japan. (1989)
13.Chiba University, Department of Pharmacology, Chiba, Japan. (1989)
14.Osaka University, Department of Medicine, Osaka, Japan. (1989)
15.University of Chicago, Department of Surgery, Chicago, Illinois. (1989)
16.Kyushu University, Department of Medicine, Fukuoka, Japan. (1989)
17.Institute of Biomedical Sciences, Academia Sinica, Taiwan., (1989)
18.Northwestern University, Department of Pharmacology, Chicago, Illinois. (1990)
19.U. of British Columbia, Dept. of Cancer Endocrinology, Vancouver, Canada. (1990)
20.Medical College of Wisconsin, Department of Urology, Milwalkee. Wisconsin (1990)
21.National Cheng Kung University, Department of Urology, Tainan, Taiwan. (1990)
22.National Chung Heing University, Institute of Genetics, Taichung, Taiwan. (1990)
23.Veterans Hospital, Department of Urology, Taichung, Taiwan. (1990)
24.National Taiwan University, Institute of Biochemistry, Taipei, Taiwan. (1990)
25.Eli Lilly and Company, Indianapolis, Indiana. (1991)
26.Hybritech Incorporated, La Jolla, California (1991)
27.W. Alton Jones Cell Science Center, Lake Placid, New York (1991)
28.University of Wisconsin Comprehensive Cancer Center, Madison. Wisconsin (1991)
29.Merck, Sharpe & Dohme Research Laboratories, Rahway. New Jersey (1991)
30.Glaxo Inc. Research Institute, Research Triangle Park, NC. (1991)
31.Tufts University, Department of Anatomy and Cell Biology, Boston. Massachusetts (1992)
32.Ohita University, Department of Dermatology, Ohita. Japan (1992)
33.Shiseido Research Center, Yokohama. Japan (1992)
34.University of Tokyo, Depart of Dermatology, Tokyo. Japan (1992)
35.Taisho Phamaceutical Company, Ohmia. Japan (1992)
36.Chiba University, Department of Urology, Chiba. Japan (1992)
37.Tokyo Medical Society, Tokyo. Japan (1992)
38.Yokohama University, Department of Dermatology, Yokohama, Japan (1992)
39.Iwate Medical University, Department of Biochemistry, Morioka, Japan (1992)
40.Krume University, Department of Dermatology, Kurume. Japan (1992)
41.University of Wisconsin, Endocrinology Program. Madison, Wisconsin (1993)
7

42.Pacific Chemical Company, Seoul. Korea (1992)
43.Korea Institute of Science and Technology, Taejon. Korea (1992)
44.National Chi-Hua University, Institute of Life Science, Hsinchu. Taiwan (1992)
45.Veterans General Hospital, Taipei. Taiwan (1992)
46.Institute of Biological Chemistry, Academia Sinica, Taipei. Taiwan (1992)
47.Merck, Sharpe & Dohme Research Laboratories, West Point, PA. (1993)
48.Marion Merrell Dow Research Institute, Cincinnati, Ohio (1993)
49.University of Southern Illinois, Department of Pharmacology, Springfield, Illinois (1993)
50.University of Wisconsin, Department of Medicine. Madison, Wisconsin (1993)
51.Glaxo Inc. Research Institute, Research Triangle Park, NC. (1993)
52.La Jolla Cancer Research Foundation, San Diego, CA. (1993)
53.PharMingen, San Diego, CA. (1993)
54.University of Wisconsin, Institute on Aging. Madison, Wisconsin (1993)
55.Acracetus Inc. Middleton, Wisconsin (1994)
56.Ohio State University, Department of Biochemistry, Columbus, Ohio (1994)
57.University of Southern California, Department of Biochemistry, Los Angeles, CA (1994)
58.Harvard University, Institute on Aging, Boston, MA (1994)
59.Institute of Zoology, Chinese Academy of Sciences, China (1994)
60.State Key Lab of Reproductive Biology, Academia Sinica, China (1994)
61.Shanghai Institute of Biochemistry, Academia Sinica, China (1994)
62.Fudan University, Department of Biology, Shanghai, China (1994)
63.Shanghai Cancer Research Center, China (1994)
64.Ther-Chiang Medical University, Department of Biochemistry, China (1994)
65.Harbor UCLA Medical Center, Department of Pathology, Torrance, CA (1994)
66.Panvera Biotech. Madison, WI (1994)
67.Memorial Sloan-Kettering Cancer Center, New York, NY (1994)
68.Yamanouchi Pharmaceutical Company, Tsukuba, Japan (1994)
69.Tokyo University of Agriculture, Department of Biochemistry, Tokyo, Japan (1994)
70.University of Wisconsin, Department of Human Oncology. Madison, WI (1994)
71.Sumitimo Chemical Company, Osaka, Japan (1994)
72.Shiseido Research Center, Yokohama. Japan (1994)
73.University of California-Los Angeles, Department of Obstetrics & Gynecology, CA (1994)
74.Institute of Biomedical Sciences, Academia Sinica, Taipei (1994)
75.National Yang-Ming Medical College, Department of Genetics, Taipei (1994)
76.U. of Texas Medical Branch at Galveston. Dept. of Pathology, Galveston, Texas (1994)
77.Case Western Reserve University, Cancer Center, Cleveland, Ohio. (1994)
78.University of Maryland, Department of Biochemistry, Baltimore, Maryland (1995)
79.Harvard University, Dana Farber Cancer Institute, Boston, MA (1995)
80.Johns Hopkins University, Department of Urology, Baltimore, Maryland (1995)
81.Uniformed Services University, Department of Surgery/Urology, Baltimore, MD (1995)
82.National Chung-Hsing University, Department of Animal Science, Taichung, Taiwan (1995)
83.National Cheng-Kung University, Department of Biochemistry, Tainan, Taiwan (1995)
84.Chung-Shan Medical College, Department of Nutritional Science, Taichung, Taiwan (1995)
85.Veterans General Hospital, Department of Surgery/Urology, Taichung. Taiwan (1995)
86.National Taiwan University, Department of Biochemistry, Taipei, Taiwan (1995)
87.Veterans General Hospital, Institute of Medical Research, Taipei. Taiwan (1995)
88.Development Center for Biotechnology, Taipei, Taiwan (1995)
89.University of California-San Francisco, Department of Pharmacology, SF, CA (1995)
90.New Jersey Medical School. Department of Biochemistry, Newark, New Jersey. (1995)
8

91.Tufts University, Department of Biology, Boston. Massachusetts (1995)
92.National Cancer Institute. Baltimore, Maryland (1995)
93.Albert Einstein College of Medicine, Department of Molecular Pharmacology, NY (!995)
94.New Jersey Medical School. Department of Urology, Newark, New Jersey. (1995)
95.Mayo Clinic, Department of Biochemistry, Rochester, MN (1995)
96.University of Wisconsin, Department of Surgery/Urology. Madison, WI (1995)
97.Merck, Sharpe & Dohme Research Laboratories, Rahway. New Jersey. (1995)
98.University of Maryland, Department of Urology, Baltimore, Maryland (1995)
99.R.W. Johnson Pharmaceutical Research Institute, Ratitan, New Jersey. (1995)
100.University of Hamburg, Institute for Hormone Research, Hamburg, Germany. (1995)
101.University of Wisconsin, Department of Biomolecular Chemistry. Madison, WI (1995)
102.University of Rochester, Department of Pathology. Rochester, NY (1995)
103.Amgen Inc. Thousand Oaks, CA (1995)
104.Yokohama University, Department of Urology, Yokohama, Japan (1995)
105.Sumitimo Chemical Company, Osaka, Japan (1995)
106.Ono Pharmaceutical Co. Osaka, Japan (1995)
107.Kyushu University, Department of Third Medicine, Fukuoka, Japan. (1995)
108.University of Occupational and Environmental Health, Kokura, Japan. (1995)
109.University of Hiroshima, Department of Urology, Hiroshima, Japan. (1995)
110.National Chi-Hua University, Department of Life Science, Hsinchu. Taiwan (1995)
111.University of Minnesota, Department of Pharmacology. Minneapolis, MN (1995)
112.National Taiwan University, Institute of Microbiology, Taipei, Taiwan (1995)
113.Institute of Molecular Biology, Academia Sinica, Taipei (1995)
114.Chiba University, Department of Urology, Chiba, Japan. (1996)
115.Oregon Health Sciences University, Endocrinology, Portland, OR. (1996)
116.Osaka University, Department of Dermatology, Osaka, Japan. (1996)
117.Harvard Medical School, MGH Cancer Center, Boston, MA (1996)
118.Kochi Medical School, Department of Urology, Kochi, Japan. (1996)
119.Women's Health Research Institute, Radnor, PA. (1996)
120.Rhone-Poulenc Rorer Research Center, Collegeville, PA. (1996)
121.University of Wisconsin, Department of Medicine. Madison, WI (1996)
122.U. of British Columbia, Dept. of Cancer Endocrinology, Vancouver, Canada. (1996)
123.Harvard Medical School, Department of Dermatology, Boston, MA (1996)
124.University of Tokyo, Institute of Molecular & Cellular Biosciences, Tokyo, Japan (1996)
125.University of Washington, Department of Urology, Seattle, WA (1996)
126.Sumitomo Chemical Company, Environmental Health Science Lab. Osaka, Japan (1996)
127.Oregon Region Primate Research Center, Beaverton, OR. (1996)
128.Saitama Medical School, Department of Biochemistry, Saitama, Japan (1996)
129.Parmingen Inc. San Diego, CA (1996)
130.National Yang-Ming University, Department of Biochemistry, Taiwan (1996)
131.University of Nebraska, Department of Biochemistry, Omaha, NB (1996)
132.University of Rochester, Department of Biochemistry, Rochester, NY (1996)
133.Institute of Biological Chemistry, Academia Sinica, Taipei (1996)
134.NYU-Mt. Sinai Medical School, Cancer Center, New York, New York. (1996)
135.University of Tokyo, Department of Urology, Tokyo, Japan (1996)
136.University of Laval, Department of Physiology-Endocrinology, Quebec, Canada (1996)
137.Ligand Pharmaceutical Co. San Diego, CA (1996)
138.Kyoto University, Department of Urology, Kyoto, Japan (1996)
139.National Taiwan University, Department of Urology, Taiwan (1996)
9

140.Northwestern University, Department of Medicine/Endocrinology, Chicago, Illinois. (1996)
141.UCLA, Department of Urology, LA, CA (1997)
142.Loyola University of Chicago, Department of Molecular Biology, Chicago, Illinois (1997)
143.University of Wisconsin, Department of Medicine/Endocrinology, Madison, WI (1997)
144.The Burnham Institute, San Diego, CA (1997)
145.Pfizer Central Research, Section of Molecular Sciences, Croton, CT (1997)
146.University of Rochester, Department of Pathology, Rochester, NY (1997)
147.Harbor-UCLA, Department of Medicine/Endocrinology, Torrance, CA (1997)
148.Institute of Biological Chemistry, Academia Sinica, Taipei (1997)
149.University of Wisconsin Comprehensive Cancer Center, Madison, WI (1997)
150.Yale University, Department of Pharmacology, New Haven, CT (1997)
151.Veterns General Hospital, Department of Surgery/Urology, Taipei. Taiwan (1997)
152.Harvard Medical School, Dana Faber Cancer Institute, Boston, MA (1997)
153.Sumitomo Chemical Company, Environmental Health Science Lab. Osaka, Japan (1998)
154.Osaka University, Department of Urology, Osaka, Japan. (1998)
155.Univ. of Occupational and Environmental Health, Dept of Urology Kokura, Japan.(1998)
156.University of Hiroshima, Department of Urology, Hiroshima, Japan. (1998)
157.Kobe University, Department of Animal Science, Kobe, Japan. (1998)
158.Bristol Myles-Squibbe Pharmaceutical Co. Princeton NJ (1998)
159.National Yang-Ming University, Department of Urology, Taiwan (1998)
160.Beijing University, Institute of Urology, China (1998)
161.Rhone-Poulenc Rorer Research Center, Collegeville, PA. (1998)
162.University of Southern California, Department of Biochemistry, Los Angeles, CA (1998)
163.Merck, Sharpe & Dohme Research Laboratories, Rahway. New Jersey. (1998)
164.University of Pennsylvania, Department of Medicine/Endocrinology, PA (1998)
165.Annual Meeting of Beijing Urology Association, Beijing, China (1998)
166.Laboratoire de Biochimie B, Hopital Necker, The Fifth University of Paris. France (1998)
167.Burnhan Institute/La Jolla Cancer Center, La Jolla, CA (1998)
168.Institut des Neurosciences, The Sixth University of Paris. France (1998)
169.Schering-Plough Research Institute, Kenilworth, NJ (1998)
170.Xiamen University, Department of Biology, Xiamen, China (1998)
171.Iinst Natl Sante Res Med, The University of Paris at South. France (1998)
172.Keio University, Department of Urology, Tokyo, Japan (1999)
173.University of Rochester, Department of Medicine/Medical Oncology, Rochester, NY (1999)
174.Yokohama City University, Department of Urology, Yokohama, Japan (1999)
175.Snow Brand Milk Products Co. Res. Institute of Life Sci. Tochigi, Japan (1999)
176.State University of New York at Buffalo, Department of Nutrition, Buffalo, NY (1999)
177.Shiseido Co. Research Institute, Yokohama, Japan (1999)
178.Chang Gung University, Department of Oncology/Medicine, Taipei, Taiwan (1999)
179.Indiana University Cancer Center, Indianapolis, IN (1999)
180.Kaosiuang Medical School, Department of Urology, Kaosiuang, Taiwan (1999)
181.Eli Lilly and Company, Indianapolis, Indiana. (1999)
182.Chang Gung University, Department of OB-GYN, Kaosiuang, Taiwan (1999)
183.Stanford University, Department of Medicine/Endocrinology, CA (1999)
184.National Taiwan University, Department of Urology, Taipei, Taiwan (1999)
185.UCSF, Department of Urology, SF, CA (1999)
186.National Cheng-Kung University, Department of Biochemistry, Tainan, Taiwan (1999)
187.Rhone-Poulenc Rorer Research Center, Collegeville, PA. (1999)
188.National Taiwan University, Institute of Biological Chemistry, Taipei, Taiwan (1999)
10

189.UC Davis Cancer Center, Sacramento, CA (1999)
190.Kyowa Hakko Kogyo Co-Pharmaceutical Research and Planning Dept., Tokyo, Japan (1999)
191.M.D. Anderson Hospital and Tumor Institute, Dept. Medical Oncology, Houston, Texas. (1999)
192.University of Mississippi, Department of Pharmacology and Toxicology, Jackson, MS. (2000)
193.University of Southern California, Department of Pathology, Los Angeles, CA (2000)
194.Parmingen Inc. San Diego, CA (2000)
195.National Cancer Institute, NIH, Bethesda, MD (2000)
196.University of North Carolina, Department of Medicinal Chemistry, Chapel Hill, NC (2000)
197.Johns Hopkins University, Department of Biology, Baltimore, Maryland (2000)
198.Wayne State University, Department of Pathology. Detroit, MI (2000)
199.New York University, Department of Pathology, New York, NY (2000)
200.Beckman Research Institute, City of Hope, Duarte, CA (2000)
201.Chang Gung University, Department of OB-GYN, Kaosiuang, Taiwan (2000)
202.Connell University, Department of Medicine/Endocrinology, New York, NY (2000)
203.National Taiwan University, Department of OB-GYN, Taipei, Taiwan (2000)
204.Oregon Regional Primate Research Center, Beaverton, OR (2001)
205.UC Davis Cancer Center, Sacramento, CA (2001)
206.National Taiwan University, Department of Pathology, Taipei, Taiwan (2001)
207.Univ, of Pittsburgh, Cancer Institute. Pittsburgh. PA (2001)
208.National Taipei Medical University, Department of Medicine, Taipei, Taiwan (2001)
209.Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China (2001)
210.National Taiwan University, Biotechnology Seminar, Taipei, Taiwan (2001)
211.University of Washington, Department of Pathology, Seattle (2002)
212.National Yang Ming Medical University, Institute of Biochemistry, Taipei, Taiwan (2002)
213.Veterans General Hospital, Department of OBGYN, Taipei. Taiwan (2002)
214.UT Southwestern Medical School, Department of Urology. Dallas (2002)
215.National Taiwan University, Department of Agriculture Chemistry, Taipei, Taiwan (2002)
216.University of North Texas, Department of Biochemistry. Dallas (2002)
217.Ma-Kai Memorial Hospital, Department of OBGYN, Taipei. Taiwan (2002)
218.UT Health Center. Institute of Biotechnology. San Antonio (2002)
219.Baylor College of Medicine, Department of Molecular and Cellular Biology. Houston (2002)
220.University of California-San Diego, Dept of Reproductive Medicine. San Diego (2003)
221.Roswell Park Cancer Institute, Buffalo, NY (2003)
222.University of Chicago, Dept of Medicine/Endocrinology, Chicago (2003)
223.Taipei Medical Univ. Dept of OBGYN. Taiwan (2003)
224.University of Wisconsin Comprehensive Cancer Center, Madison (2003)
225.University of Southern California, Dept of Microbiology, Los Angeles, CA (2003)
226.Taipei Veterans General Hospital, Dept. of OBGYN, Taiwan (2003)
227.Case Western Reserve Univ. Dept of Biochemistry, Cleveland (2003)
228.Ohio State University, Dept of Medicine Chemistry, Columbus, Ohio (2003)
229.University of California-Los Angeles, Dept of OBGYN, Los Angeles, CA (2003)
230.Cleveland Clinic Foundation, Dept of Tumor Biology, Cleveland, (2003)
231.TAA at Columbus, Columbus, Ohio (2003)
232.John Hopkins University, Dept of Biochemistry and Molecular Biology, Baltimore (2003)
233.Cornell University, Dept of Urology, New York, (2003)
234.TAA at Cleveland, Cleveland, Ohio (2003)
235.NATPA at Southern California, LA (2003)
236.TAA at Cincinnati, Ohio (2003)
11

238.MD Anderson Cancer Center, Dept of Cancer Biology, Houston, (2004)
239.TAA at Houston, TX (2004)
240.TAA at Chicago, Ill (2004)
241.University North Carolina, Dept of Biochemistry, Chapel Hill, (2004)
242.TAA at North Carolina, Raleigh, NC (2004)
243.Kao Hsiung Medical University, Dept. of Urology, Kao Hsiung, Taiwan (2004)
244.Cheng-Gong University School of Medicine, Tainan, Taiwan (2004)
245.China Medical University, School of Medicine, Taichung, Taiwan (2004)
246.Shanghai Biochemistry Institute, Shanghai, China (2004)
247.University of Nagoya, Dept. of Neuroscience, Nagoya, Japan (2004)
248.University of Osaka, Dept. of Dermatology, Osaka
249. Chang-Gong University, Dept. of Medical Technology, Taiyuan, Taiwan (2004)
250. UCSF, Dept. of Cell Biology, San Fran, CA (2005)
251. National Taiwan University, Dept. of Oncology, Taipei, Taiwan (2005)
252. Taipei Medical University, Dept. of Ob GYN, Taipei, Taiwan (2005)
253. Emory University School of Medicine, Atlanta, GA (2005)
254. University of Wisconsin, Dept. of Oncology, Madison, WI (2005)
255. Baylor College of Medicine, Endocrinology, Houston, TX (2005)
256. China Urology Association Annual Meeting, Hang Zhou, China (2005)
257. Zer Jiang University Dept. of Urology, Hang Zhou, China (2005)
258. Georgetown University Cancer Center, Washington, D.C. (2006)
259. University of Rochester Dept. of Pathology, Rochester, NY (2006)
260. University of Maryland Dept. of Biochemistry, Baltimore, MD (2006)
261. Wayne State University Dept. of Pathology, Detroit, MI (2006)
262. Chung-Tsing University Dept of Life Science, Taichung, Taiwan (2006)
263. Cheng-Gong University School of Medicine, Tainan, Taiwan 2006
264. University of Rochester Dept. of Neurology, Rochester, NY (2006)
265. Tzu-chi University School of Medicine, Hualien, Taiwan (2006)
266. Development Center for Biotechnology, Taipei, Taiwan (2006)
267. Department of Medicine, Fu-Zen University, Taipei, Taiwan (2007)
268. Department of Urology, Uniform University, DC (2007)
269. Department of Life Science. Xiaman University, Xiaman, China (2007)
270. Department of Urology, Zer Jiang University, HangZhou, China (2007)
271. Department of Urology, University of California-San Francisco, CA (2008)
272. Department of Medicine/Endocrinology, Boston, MA (2008)
273. Department of Surgery/Urology, Kansas City, MO (2008)
274. Department of Urology, Univ. of George-Augusta (2008)
275. Department of Medical Oncology, MD Anderson, Houston, TX (2008)
276. Dana Faber Cancer Institute, Harvard University, Boston, MA (2008)
277. Department of Urology, U. of British Columbia, Vancouver, Canada. (2008)
279. Hormel Institute, University of Minnesota-Austin, MN (2008)
280. Department of Urology, Mayo Clinics, Rochester, MN (2008)
281. Department of Pathology, University of Minnesota, Minneapolis, MN (2008)
282. Department of Urology, University of California-San Francisco, CA (2008)
283. Department of Urology, Northwestern University, Chicago, IL (2009)
284. Department of Dermatology, University of California-Davis, CA (2009)
12

285. Department of Urology, University of Michigan, Ann Arbor, MI (2009)
286. Institute of Food Science, National Taiwan University, Taipei, Taiwan (2009)
287. Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio (2009)
13

PUBLICATIONS
Total 300 including 1 Nature Medicine /1 Science /1 Lancet /1 JCI /2 J Exp Med/1JNCI/ 29 PNAS
/50 JBC /10 MCB and >200 in Endocrinology or Cancer related Journals
Editor of Book: Androgens and Androgen Receptor: Mechanisms, Functions, and Clinical
Applications (Published by Kluwer Academic Publishers-2002)
Editor of Book: Prostate Cancer: Basic Mechanisms and Therapeutic Approaches (Published by
World Scientific-2005)
1.
Liao S, Hiipakka RA, Schilling K, Oberhauser AK, Chang C
, and Judge SM “Cellular dynamics of androgen receptor and protein induction in rat ventral prostate.” Prog. Clin. Biol.,
Res., (1981):75A, 381-9. PMID: 7339626.
2.
Liao S, Chang C
, and Saltman AG “Androgen-receptor interaction: An overview.” Nobel symposium, Sweden, No.57, (Eriksson H, and Gustafsson JA eds.) (1983):pp. 407-418,
Elsevier Science Publishing, New York.
3.
Liao S, Witte D, Schilling K, and Chang C “The use of a hydroxylapatite-filter steroid receptor assay method in the study of the modulation of androgen receptor interaction.” JSBMB.,
(1984):20(1), 11-7. PMID: 6323860.
4.
Liao S, Chang C
, Witte D, Saltzman AG, and Hiipakka RA “Modulation of androgen receptor and androgen-dependent enhancement and repression of protein synthesis.” in Regulation of
Androgen Action, (Bruchovsky N, Chapdelaine A, and Neumann F, eds.) (1985):pp.149-154,
Congressdruck R. Bruckner, Berlin.
5.
Liao S, and Chang C “Cellular dynamics and control of androgen receptor activity.” in
Interaction of Steroid Hormone Receptors with DNA (Sluyser M, ed.) (1985):pp.190-201, Ellis
Horwood Ltd. Publishers, Chichester, England.
6.
Chang C
, Hiipakka RA, and Liao S “Spermine-binding protein of rat ventral prostate: phosphorylation, cDNA structure, and gene expression.” Proc. Intl. Conf. Polyam. Life
Sci.,(1986):99-100. PMID: none.
7.
Chang C and Liao S “Topographic recognition of cyclic hydrocarbons and related compounds by receptors for androgens, estrogens, and glucocorticoids.” J. Steroid Biochem., (1987):27(1-
3), 123-31. PMID: 3695475.
8.
Chang C
, Saltzman AG, Hiipakka RA, Huang IY, and Liao S “Prostatic spermine-binding protein: cloning and nucleotide sequence of cDNA, amino acid sequence, and androgenic control of mRNA level.” J. Biol. Chem., (1987):262(6), 2826-21. PMID: 3818623.
9.
Saltzman AG, Hiipakka RA, Chang C , and Liao S “Androgen repression of the production of a 29 kilodalton protein and its mRNA in the rat ventral prostate.” J. Biol. Chem., (1987):262
(1), 1,432-7. PMID: 3793731.
14

10.
Chang C , Saltzman AG, Sorensen NS, Hiipakka RA, and Liao S “Identification of glutathione
S-transferase Yb1 mRNA as the androgen-repressed mRNA by cDNA cloning and sequence analysis.” J. Biol. Chem., (1987):262(25), 11901-3. PMID: 3040722.
11.
Chang C , Kokontis J, Chang C-T, and Liao S “Cloning and sequence analysis of the rat ventral prostate glucocorticoid receptor cDNA.” Nucleic Acids Res., (1987); 15(22):9603. PMID:
3684608.
12.
Liao S, Chang C , Sorensen NS, Chang C-T, and Hiipakka RA “Modulation of androgen receptor activity and the effect of androgens on gene expression for specific proteins.” in
Hormonal Therapy of Prostatic Disease: Basic and Clinical Aspects (Motta, M., and Serio, M. eds) (1987):pp. 48-62, Medicom Europe, The Netherlands.
13.
Anderegg RJ, Carr SA, Huang I-Y, Hiipakka RA, Chang C
, and Liao S “Correction of the cDNA-derived protein sequence of prostatic spermine binding protein: Pivotal role of tandem mass spectrometry in sequence analysis.” Biochemistry, (1988):27(12), 4214-21. PMID:
3166977.
14.
Chang C and Liao S “Gene expression and structure analysis of cDNA's for androgen-sensitive proteins and different forms of steroid-receptors.” Progress in Cancer Research and Therapy,
(1988):35, 43-48. PMID: none.
15.
Chang C
, Kokontis J, and Liao S “Molecular cloning of human and rat complementary DNA encoding androgen receptors.” Science, (1988):240(4850), 324-326. PMID: 3353726.
16.
Chang C
, Kokontis J, and Liao S “Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors.” Proc. Natl. Acad. Sci., (1988):85(19), 7211-5.
PMID: 3174628.
17.
Chang C and Kokontis J “Identification of a new member of steroid receptor superfamily by cloning and sequence analysis.” BBRC., (1988):155(2), 971-7. PMID: 3421977.
18.
Liao S, Chang C
, Kokontis J, Popovich T, and Hiipakka RA “Structure and intranuclear dynamics of androgen receptors.” in The Steroid/Thyroid Hormone Receptor Family and Gene
Regulation. (Gustafsson, JA., Eriksson, H. and Carlstedt-Duke, J. eds).(1989):83-92,
Congressdruck R. Bruckner, Berlin, Burkhauser Verlag Basel.
19.
Buttyan R, Olsson CA, Pintar J, Chang C
, Bandyk M, Ng PY, and Sawczuk IS “Induction of the TRPM-2 gene in cells undergoing programmed death.” MCB., (1989):9(8), 3473-81. PMID:
2477686. PMC362394.
20.
Chang C, Whelan CT, Popovich TC, Kokontis J, and Liao S “Fusion proteins containing androgen receptor sequences and their use in the production of poly- and monoclonal antiandrogen receptor antibodies.” Endocrinology, (1989):125(2), 1097-9. PMID: 2666105.
21.
Chang C
, Chodak G, Sarsac E, Takeda H, and Liao S “Prostate androgen receptor: immunohistological localization and mRNA characterization.” J. Steroid Biochem.,
(1989):34(1-6), 311-313. PMID: 2626023.
15

22.
Chang C
, Lau L, Liao S, and Kokontis J “Characterization of new members of steroid receptor superfamily.” in The Steroid/Thyroid Hormone Receptor Family and Gene Regulation.
(Gustafsson JA, Eriksson H, and Carlstedt-Duke J eds.) (1989):183-195, Congressdruck R.
Bruckner, Berlin, Burkhauser Verlag Basel.
23.
Chang C, Kokontis J, Acakpo-Satchivi L, Liao S, Takeda H, Chang Y “Molecular cloning of new human TR2 receptors: A class of steroid receptor with multiple ligand-binding domains.”
BBRC., (1989):165(2), 735-41. PMID: 2597158
24.
Chang C , Kokontis J, Liao S, and Chang Y “Isolation and characterization of human TR3 receptor: A member of steroid receptor superfamily.” J. Steroid Biochem., (1989):34(1-6), 391-
5. PMID: 2626032.
25.
Chang C
, Kokontis J, Swift S, and Liao S “Molecular cloning and structural analysis of complementary DNA of human and rat androgen receptors.” Prog. Clin. Biol. Res.,
(1990);322:53-63. PMID: 1968256
26.
Simerly RB, Chang C
, Muramatsu M, and Swanson LW “The distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization study.”
Journal of Comparative Neurology, (1990):294(1), 76-95. PMID: 2324335.
27.
Sai T, Seino S, Chang C, Trifiro M, Pinsky L, Mhatre A, Kaufman, M, Lambert B, Trapman J,
Brinkmann AO, Rosenfield RL, and Liao S “An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity.” American Journal of Human
Genetics, (1990):46(6), 1095-100. PMID: 2339702. PMC1683844.
28.
West NB, Chang C
, Liao S, and Brenner RM “Localization and regulation of estrogen, progestin and androgen receptors in the seminal vesicle of the rhesus monkey.” J. Steroid
Biochem., (1990):37. 11-21. PMID: 2242343.
29.
Imperato-McGinley J, Ip NY, Gautier T, Neuweiler J, Gruenspan H, Liao S, Chang C, and
Balazs I “DNA linkage analysis and studies of the androgen receptor gene in a large kindred with complete androgen insensitivity.” American Journal of Medical Genetics, (1990):36(1),
104-8. PMID: 2333898.
30.
Masai M, Sumiya H, Akimoto S, Yatani R, Chang C, Liao S, and Shimazaki J
“Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates.” The Prostate, (1990):17(4), 293-300. PMID: 1701248.
31.
Kranc DM, Chodak GW, and Chang C “Androgen receptor staining in heterogeneous samples of normal, hyperplastic, and neoplastic human prostate.” Surgical Forum, (1990):41, 687-689.
PMID: none.
32.
Takeda H, Chodak GW, Mutchnik SE, Nakamoto T, and Chang C “Immunohistochemical localization of androgen receptors with mono-and polyclonal antibodies to androgen receptor.”
Journal of Endocrinology, (1990):126(1), 17-25. PMID: 2199591.
16

33.
Matusik RJ, Cattini PA, Leco KJ, Sheppard PC, Nickel BE, Neubauer BL, Davie JR, Chang C ,
Liao S, Matuo Y, and McKeehan WL “Regulation of gene expression in the prostate.” in
Molecular and Cellular Biology of Prostate Cancer, (1991):299-314, Plenum, New York.
34.
Takeda H, Nakamoto T, Kokontis J, Chodak GW, and Chang C “Autoregulation of androgen receptor expression in rodent prostate: Immunohistochemical and in situ hybridization analysis.” BBRC, (1991):177(1), 488-96. PMID: 2043134.
35.
Kokontis J, Nakamoto T, and Chang C “Structural analysis and gene expression of TR2 receptor and TR3 receptor.” Molecular and Cellular Biology of Prostate Cancer, (1991):229-
234. Plenum, New York.
36.
Takeda H, and Chang C
“Immunohistochemical and in situ hybridization analysis of androgen receptor expression during the development of mouse prostate gland.” Journal of
Endocrinology, (1991):129(1), 83-91. PMID: 2030333.
37.
Trifiro M, Gottlieb B, Pinsky L, Kaufman M, Prior L, Belsham DD, Wrogemann K, Brown CJ,
Willard HF, Trapman J, Brinkmann AO, Chang C,
Liao S, Sergovich F, and Jung J “The
56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor gene.” Molecular and Cellular Endocrinology, (1991):75(1), 37-47. PMID: 2050265.
38.
Chang C
, Takeda H, and Kokontis J “cDNA cloning, antibody production and immunohistochemical localization of the androgen receptor.” Molecular and Cellular Biology of Prostate Cancer, (1991):235-241, Plenum, New York.
39.
Mestayer C, Gabou L, Portois MC, Boucekkine C, Chang C, and Mowszowicz I. “Expression du gene durpecepteur des androgenes chez des sujets normaux et des patients presentant une insensibilite complete aux androgenes.” Annales d'Endocrinologie, (1991):52, 431-4. PMID: none.
40.
Sanborn BM, Caston LA, Chang C, Liao S, Speller R, Porter LD, and Ku CY “Regulation of androgen receptor mRNA in rat sertoli and peritubular cells.” Biology Reproduction,
(1991):45(4), 634-41. PMID: 1751639.
41.
Kokontis J, Liao S, and Chang C “Transcriptional activation by TR3 receptor, a member of steroid receptor superfamily.” Receptor, (1991):1(4), 261-70. PMID: 184321.
42.
Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, and Chang C “Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic, and neoplastic human prostate.” Journal of Urology, (1992): (3 Pt 2):798-803. PMID: 1371552.
43.
Nakamoto T, Chang C , Li A, and Chodak GW “Basic fibroblast growth factors in human prostate cancer cells.” Cancer Research, (1992):52(3), 571-7. PMID: 1732045.
44.
Prior L, Bordet S, Trifiro MA, Mhatre A, Kaufman M, Pinsky L, Wrogeman K, Belsham DD,
Pereira F, Greenberg C, Trapman J, Brinkmann AO, Chang C, and Liao S “Replacement of arginine 773 by cysteine or histidine in the human androgen receptor causes complete androgen
17

insensitivity with different receptor phenotypes.” American Journal of Human Genetics,
(1992):51(1), 143-55. PMID: 1609793. PMC1682864.
45.
Gipp JJ, Chang C, and Mulcahy RT “Cloning and nucleotide sequence of a full-length cDNA for human liver

glutamylcysteine synthetase.” BBRC, (1992):185(1), 29-35. PMID: 1350904.
46.
Leav I, Kwan PW, Merk FB, Chang C, and Ho SM “Immunohistochemical and in situ hybridization studies of androgen receptor expression in a transplantable androgen-independent prostate carcinoma cell line of AIT noble rats.” Laboratory Investigation, (1992):67, 788-95.
PMID: 1460869.
47.
Jiang S-Y, Wolf DM, Yingling JM, Chang C, and Jordan VC “An estrogen receptor positive
MCF-7 clone that is resistant to antiestrogens and estradiol.” Molecular and Cellular
Endocrinology, (1992):90(1), 77-86. PMID: 1301400.
48.
Chang C,
Wang C, Deluca HF, Ross TK, and Shih CC “Characterization of an human androgen receptor overexpressed in the baculovirus system.” Proc. Natl. Acad. Sci.,
(1992):89(13), 5946-50. PMID: 1631078. PMC402115.
49.
Kaku A, Chang C, Tamura T, Okamoto T, and Yoshimura Y “Immunolocalization of androgen receptor in the cloacal gland of male Japanese quail (Coturnis coturnix japonica).”
Japanese Poultry Science, (1993):30, 413-418. PMID: none.
50.
Rennie PB, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoeck R, Hamel
A, Bock ME, MacDonald BS, Nickel BE, Chang C , Liao S, Cattini PA, and Matusik RJ
“Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene.” Mol. Endocrinology, (1993):7, 23-36. PMID: none.
51.
Mowszowicz I, Lee HJ, Chen HT, Mestayer C, Portois MC, Carbrol S, Mauvais-Jarvis P, and
Chang C “A point mutation in the second zinc-finger of the DNA-binding domain of the androgen receptor gene causes complete androgen insensitivity in two siblings with receptorpositive androgen resistance.” Mol. Endocrinology, (1993):7(7), 861-9. PMID: 8413310.
52.
Lee HJ, Kokontis J, Wang KC, and Chang C
“The use of a DNA-binding domain replacement method for the detection of a potential TR3 orphan receptor response element in the mouse mammary tumor virus long terminal repeat.” BBRC., (1993):194(1), 97-103. PMID: 8392847.
53.
Yoshimura Y, Chang C, Okamoto T, and Tamura T “Immunolocalization of androgen receptor in the small, preovulatory and postovulatory follicles of laying hens.” General and Comparative
Endocrinology, (1993):91(1), 81-9. PMID: 8405895.
54.
Mowszowicz I, Lee H-J, Portois M-C, Kuttenn F, and Chang C
“Complete androgen insensitivity due to a single base substitution in exon 8 of the steroid-binding domain of the androgen receptor.” Endocrine, (1993):1, 203-9. PMID: none.
55.
Zhang YL, Wang C, Wilding G, and Chang C “Identification of an androgen-induced C3-P4
DNA binding protein in the cytosol of rat ventral prostate.” BBRC., (1993):195(2), 710-6.
PMID: 8373409.
18

56.
Chang C, Saltzman AG, Lee H, Uemura H, Su C, Chodak GW, Nakamoto T, LeBeau M,
Espinosa R, Davis E, Lemons R, Sivak L, and Shih C “Genomic structure, chromosomal localization and expression of an inducible TR3 orphan receptor: A member of the steroid receptor superfamily.” Endocrine, (1993):1, 541-9. PMID: none.
57.
Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo Y, Nakamura T, Ouchi Y, Chang
C, and Orimo H
“Immunocytochemical identification of androgen receptors in mouse osteoclast-like multinucleated cells.” Calcified Tissue International, (1994):54(4), 325-6.
PMID: 8062148.
58.
Mizokami A, Yeh S, and Chang C “Identification of 3', 5' cyclic adenosine monophosphate response element and other cis -acting elements in human androgen receptor gene promoter.”
Mol. Endocrinology, (1994):8(1), 77-88. PMID: 8152432.
59.
Young WJ, Roecker EB, Weindruch R, and Chang C “Quantitation of androgen receptor mRNA by competitive reverse transcription-polymerase chain reaction.” Endocrine, (1994):2,
321-9. PMID: none.
60.
Mizokami A, and Chang C “Induction of translation by 5'-untranslated region of human androgen receptor mRNA.” J. Biol. Chem., (1994):269(41), 25655-9. PMID: 7929269.
61.
Lustig RH, Hua P, Smith LS, Wang C, and Chang C “An in vitro model for the effects of androgen on neurons employing androgen receptor-transfected PC12 cells.” Mol. Cel. Neuro.
Sciences, (1994):5(6), 587-96. PMID: 7704433.
62.
Chang C , Da Silva SL, Ideta R, Lee Y-F, Yeh S, and Burbach JP “Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily.” PNAS., (1994): 91(13):6040-4.
PMID: 8016112. PMC44133.
63.
Pugh TD, Chang C
, Uemura H and Weindruch R “Prostatic localization of spontaneous early invasive carcinoma in Lobund-Wistar rats.” Cancer Research, (1994):54(22), 5766-70. PMID:
7525050.
64.
Joubert Y, Tobin C, Lebart MC and Chang C “Ultrastructural localization of androgen receptors in levator ani muscle in the rat.” Proc. Intl. Conf. Elec. Microscopy, (1994):13, 325-
326. PMID: none.
65.
Ideta R, Yeh S, Lee YF, Adachi K, Takeda H, Su C, Saltzman A and Chang C “Gene expression of the androgen repressed rat TR2 orphan receptor: a member of steroid receptor superfamily.” Endocrine, (1995):3, 277-83. PMID: none.
66.
Lopes da Silva S, Van Horssen AM, Chang C, Burbach JP “Expression of nuclear hormone receptors in the rat supraoptic nucleus.” Endocrinology, (1995):136(5), 2276-2283. PMID:
7720676.
19

67.
Garcias-Arenas R, Lin FF, Lin DL, Jin LP, Shih CY, Chang C , and LinM-F “The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate carcinoma cells.”
Mol. Cell Endocrinol., (1995):111(1):29-37.PMID: 7649350
68.
Chang C , Saltzman A, Yeh S, Young WJ, Keller E, Lee H-J, Wang C, and Mizokami A
“Androgen receptors: an overview.” Critical Reviews in Eukaryotic Gene Expression,
(1995):5(2), 97-125. PMID: 8845584.
69.
Uemura H, Mizokami A, and Chang C
“Identification of a new enhancer in the promoter region of human TR3 orphan receptor gene: a member of steroid receptor superfamily.” J. Biol.
Chem., (1995):270(10), 5427-33. PMID: 7890657
70.
Lee HJ and Chang C “Identification of human TR2 orphan receptor response element in the transcriptional initiation site of the Simian Virus 40 major late promoter.” J. Biol. Chem.
(1995):270(10), 5434-40. PMID: 7890658.
71.
Lin TM, Young WJ, and Chang C “Multiple functions of the TR2-11 orphan receptor in modulating activation of two key cis -acting elements involved in the retinoic acid signal transduction system.” J. Biol. Chem., (1995):270(50), 30121-8. PMID: 8530418.
72.
Lee HJ, Lee Y, Burbach P, and Chang C
“Suppression of gene expression on the Simian Virus
40 major late promoter by human TR4 orphan receptor: a member of steroid receptor superfamily.” J. Biol. Chem., (1995):270(50), 30129-33. PMID: 8530419.
73.
Yuan Z, Zhang Y , Chang C and Zhang YL “Differential regulation of glutathione S-transferase
-Yb1 mRNA levels in rat prostate, liver, and brain by androgen.” Cell Research, (1995):55,
235-242. PMID: none.
74.
Chang C , Lin T-M, Hsiao P, Su C, Riebe J, and Lin D-L “Androgen-responsive genes.” In:
Pharmacology, Biology and Clinical Application of Androgens. (Basin C, and Swarlorf G eds).
(1996):pp. 65-71, Wiley-Liss, Inc.
75.
Su CY, Chang C , and Lai C-C “Induction of heat shock proteins by exercise.” in
Pharmacology in Exercise and Sports. (Somani SM ed), (1996):pp. 147-167, CRC Press,
London.
76.
Lin T, Lustig RH, and Chang C “The role of androgens-androgen receptor in immune system activity.” in: The Physiology of Immunity, (Marsh JA and Kendall MD eds) (1996): pp. 263-
276, CRC Press, Boca Raton FL.
77.
Keller ET, Ershler WB, and Chang C “The androgen receptor: a mediator of diverse responses.” Frontiers in Bioscience, (1996):1: d59-71. PMID: 9159212.
78.
Yeh S and Chang C
“Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.” Proc. Natl. Acad. Sci., (1996):93(11):5517-21.
PMID: 8643607.
20

79.
Lee HJ, Young WJ, Shih CY and Chang C “Suppression of the human erythropoietin expression gene by the TR2 orphan receptor: a member of steroid receptor superfamily.” J. Biol.
Chem., (1996):271(17), 10405-12. PMID: 8626614.
80.
Lin DL and Chang C
“P53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of steroid receptor superfamily.” J. Biol. Chem., (1996): 71(25):14649-52.PMID: 8663350.
81.
Lee HJ, Mowszowicz I, and Chang C “The first detection of complete androgen insensitivity with no mutation in the coding sequence of the androgen receptor gene.” Frontiers in
Bioscience, (1996): 1: a34-8. PMID: 9159192
82.
Keller ET, Chang C, and Ershler WB “Inhibition of NFkB activity through maintenance of
-mediated repression of the interleukin-6 promoter.” J. Biol. Chem., (1996): 271(42):26267-75. PMID: 8824277.
83.
Yeh S, Miyamoto H, and Chang C
“Hydroxyflutamide may not always be a pure antiandrogen.” The Lancet, (1997): 349(9055):852-3. PMID: 9121269.
84.
Obana N, Chang C, and Uno H “Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque.”
Endocrinology, (1997):138(1), 356-1. PMID: 8977424.
85.
Miyamoto H, Yeh S, Kinoshita H, Fujimoto N, Nishimura K, Inui S, Mizokami A, Uemura H, and Chang C
“Androgen receptor and androgen receptor cofactors in prostate.” Proc. Jap. Nat.
Conf. Andrology, (1997):1-4. PMID: none .
86.
Yeh S and Chang C “The effect of androgens and 17 
-estradiol on the androgen receptor transcriptional activity in the presence of the androgen receptor coactivator ARA70 in human prostate DU145 cells.” from: Current Advances in Andrology, (Waites G. Frick J and Baker G ed) (1997):pp. 17-22 Monduzzi Editore Italy.
87.
Young WJ, Smith SM, and Chang C “Induction of the intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFR)

gene by the TR4 orphan receptor.” J. Biol. Chem.,
(1997):272(5), 3109-16. PMID: 9006963.
88.
Lee YF, Pan HJ, Burbach JP, Morkin E, and Chang C
“Identification of direct-repeat 4 as a positive regulatory element for the human TR4 orphan receptor: a modulator for the thyroid hormone target genes.” J. Biol. Chem., (1997):272(18), 12215-20. PMID: 9115296.
89.
Yeh S and Chang C
“ARA70, Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.” Worldwide Documents in Prostatic Cancer
& BPH (1997):5, 2-3. PMID: none.
90.
Lin TM, and Chang C “Cloning and Characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone.” Proc. Natl. Acad. Sci.,
(1997):94(10), 4988-93. PMID: 9144177.
21

91.
Wiren KM, Zhang X, Chang C, Keenan E, and Orwoll ES “Transcriptional up-regulation of the human androgen receptor by androgen in bone cells.” Endocrinology, (1997):138(6), 2291-
300. PMID: 916501.
92.
Magi-Galluzzi C, Xu X, Hlarty L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, and Loda M
“Heterogeneity of androgen receptor content in advanced prostate cancer.” Modern Pathology,
(1997): 10(8):839-45. PMID: 9267828
93.
Chang C, Lee HJ, Lee YF “Identification of the human aldolase A gene as the first induced target for the human TR2 orphan receptor: a member of the steroid hormone receptor superfamily.” Biomed. Biophysic. Res. Commun., (1997):235(1), 205-11. PMID: 9196064.
94.
Schirar A, Chang C, and Rousseau JP “Localization of androgen receptor in nitric oxide synthase- and vasoactive intestinal peptide-containing neurons of the major pelvic ganglion innervating the rat penis.” Journal of Neuroendocrinology, (1997):9(2), 141-50. PMID:
9041368.
95.
Lin MF, Meng TC, Roa PS, Chang C,
Schonthal AH, and Lin FF “Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines.” J. Biol. Chem., (1998):273(10), 5939-47. PMID: 9488733
96.
Uemura H and Chang C
“Antisense TR3 orphan receptor can increase prostate cancer cell viability with Etoposide treatment.” Endocrinology, (1998):139(5), 2329-34. PMID: 9564841.
97.
Lin DL Wu SQ, and Chang C “The genomic structure and chromosomal location of the human
TR2 orphan receptor: a member of steroid receptor superfamily.” Endocrine,
(1998): 8(2):123-
34. PMID: 9704569
98.
Lee YF, Young WJ, Burbach JP, and Chang C “Negative feedback control of the retinoidretinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor: a member of steroid receptor superfamily.” J. Biol. Chem., (1998):273(22), 13437-43. PMID: 9593676.
99.
Yeh S, Miyamoto H, Shima H, and Chang C “From estrogen to androgen receptor: a new pathway for sex hormone in prostate.” Proc. Natl. Acad. Sci., (1998): 95(10):5527-32.PMID:
9576916
100.
Miyamoto H, Yeh S, Wilding G, and Chang C “Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.” Proc.
Natl. Acad. Sci., (1998) 5(13):7379-84. PMID: 9636157 .
101.
Hwang SB, Burbach JP, and Chang C, "TR4 orphan receptor crosstalks to chicken ovalbumin upstream protein-transcription factor and thyroid hormone receptor to induce the transcriptional activity of the human immunodeficiency virus type-1 long terminal repeat." Endocrine, (1998):
8(2), 169-75. PMID: 9704574.
102.
Su CY, Chong KY, Owen OE, Dillmann WH, Chang C , Lai CC
“Constitutive and inducible hsps70s are involved in oxidative resistance evoked by heat shock or ethanol.” J. Mol. Cell
Cardiology, (1998):30(3), 587-98. PMID: 9515034.
22

103.
Chong KY, Lai CC, Lille S, Chang C
, Su CY “Stable overexpression of the constitutive form of heat shock protein 70 confers oxidative protection.” J. Mol. Cell Cardiology, (1998):30(3),
599-608. PMID: 9515035.
104.
Miyamoto H, Yeh S, Huang S-B, Fugimoto N, Hsiao P, Ting H, Inui S, Nishimura K, Wang C,
Uemura H, Kang H, and Chang C
“The Androgen Receptor Coregulator ARA70.” in
Molecular Basis of Sex Hormone Receptor Function, (Gronemeyer H, Fugymann U and
Parczyk ed) (1998) pp. 43-51, Springer, Berlin.
105.
Young WJ, Lee YF, Smith SM, and Chang C “A bi-directional regulation between the
TR2/TR4 orphan receptors (TR2/TR4) and the ciliary neurotrophic factor (CNFT) signaling pathway.” J. Biol. Chem., (1998):273(33), 20877-85. PMID: 9694834.
106.
Chen X, Zachar V, Chang C , Ebbesen P, and Liu X
“Differential expression of Nur77 family members in human T-lymphotropic virus type 1-infected cells: transactivation of the
TR3/Nur77 gene by Tax protein.” J. of Virology, (1998): 72(8):6902-6.PMID: 9658143.
107.
Young WJ and Chang C “Ontogeny and autoregulation of androgen receptor mRNA expression in the nervous system.” Endocrine, (1998): 9(1), 79-88. PMID: 9798734.
108.
Chang C and Pan, H-J “Thyroid hormone direct repeat 4 response element is a positive regulatory element for the human TR2 orphan receptor, a member of the steroid receptor superfamily.” MCB., (1998):189(1-2), 195-200. PMID: 9879671.
109.
Mu X. Young WJ, Liu YX, Uemura H, and Chang C
“Induction of an intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFR α ) gene by the TR3 orphan receptor.”
Endocrine, (1998):9(1), 27-32. PMID: 9798727.
110.
Pan H-J, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, and Chang C “Evaluation of
RU58841 as an antiandrogen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of Stumptailed Macaques.” Endocrine ,
(1998):9(1), 39-43. PMID: 9798729.
111.
Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, and Chang C
“Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells.” BBRC., (1998);248(2):361-7.PMID: 9675141.
112.
Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG,
Isaacs WB, and Nassif N “Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.” Cancer
Research ,(1998): 58(23):5310-4.PMID: 9850055.
113.
Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, and Castagna G
“Androgen receptors in ovarian tumors: correlation with Oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study.” J. Exp. Clin. Cancer
Res., (1998):17(2), 231-7. PMID: 9700586
23

114.
Miyamoto H, Yeh S, Lardy H, Messing E, and Chang C “Delta5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.” Proc. Natl. Acad. Sci.,
(1998): 95(19):11083-8.PMID: 9736693 .
115.
Cardillo MR, Petrangeli E, Ravenna L, Salvatori L, Chang C, DiSilverio F
“Immunohistochemical quantification and determination of Cathepsin D in prostatic neoplasia: correlation with steroid.” Applied Immunohistochemistry,
(1998):6(3), 133-139. PMID: none .
116.
Mu XM, Liu YX and Chang C “Mechanism of the interaction between orphan receptor TR3 and cis-acting element in CNTFRa gene.” Chinese J. Biochemistry and Molecular Biology,
(1998):14, 484-92. PMID: none .
117.
Kang HY, Yeh S, Fujimoto N, and Chang C
“Cloning and characterization of human prostate coactivator, ARA54, a novel protein that associates with the androgen receptor.” J. Biol. Chem.,
(1999):274(13), 8570-6. PMID: 10085091.
118.
Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK and
Chang C
“Differential induction of androgen receptor transcriptional activity by selective androgen receptor coactivators.” Keio J. Medicine, (1999):48(2):87-92. PMID: 10405524.
119.
Wang C, Young WJ, and Chang C “Androgen effects on the solubility and conformational change of androgen receptor in baculovirus expression system.” MCB., (1999):195(1-2), 19-23.
PMID: 10395065.
120.
Inui, S, Lee YF, Haake AR, Goldsmith LA, and Chang C
“Induction of TR4 orphan receptor by retinoic acid in human HaCaT keratinocytes.” J. Investigative Dermatology, (1999)
: 112(4),
426-31. PMID: 10201524.
121.
Heinlein CA, Ting H-J, Yeh S, and Chang C “Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma.” J. Biol. Chem.,
(1999):274(23), 16147-52. PMID: 10347167
122.
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, and Chang C “From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.” Proc. Natl. Acad. Sci., (1999):96, 5458-63,
PMID: 10318905.
123.
Lee HJ, Lee YF, and Chang C “Identification of the histamine H1 receptor gene as a differentially repressed target of the human TR2 orphan receptor.” MCB., (1999):194(1-2),
199-207. PMID: 10391141.
124.
Lee YF. Young W-, Lin WJ, Shyr CR, and Chang C “Differential regulation of direct repeat 3
Vitamin D
3
and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor.” J. Biol. Chem., (1999):274(23), 16198-205. PMID: 10347174.
125.
Hsiao P and Chang C “Isolation and characterization of ARA160 as an androgen receptor Nterminal associated coactivator in human prostate cells.” J. Biol. Chem., (1999):274(32),
22373-9. PMID: 10428808.
24

126.
Hsiao P, Lin D, Nakao K, and Chang C “The linkage of the Kennedy’s neuron disease to
ARA24, the first identified androgen receptor poly-glutamine region-associated coactivator.” J.
Biol. Chem., (1999): 274(29):20229-34. PMID: 10400640.
127.
Yang CR, Yeh S, Leskov K, Odegaard E, Hsu HL, Chang C , Kinsella TJ, Chen DJ, Boothman
DA. “Isolation of Ku70-binding proteins (KUBs).” Nucleic Acid Res., (1999):27(10), 2165-74.
PMID: 10219089.
128.
Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, and Chang C
“Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.” J. Biol. Chem.,
(1999):274(12), 8316-21, PMID: 10075738.
129.
Lee YF, Shyr CR, Thin TH, Lin WJ and Chang C “Convergence of two repressors through heterodimer formation of androgen receptor and TR4 orphan nuclear receptor: a new signaling pathway in the steroid receptor superfamily.” Proc. Natl. Acad. Sci., (1999):96(26), 14724-9.
PMID: 10611280.
130.
Shih CC, Young WJ, Wang CH, Jin LP, Ji XD, Guan Q, Wang M, and Chang C “Monoclonal anti-androgen receptor antibodies: production, characterization, and potential diagnostic applications.” MCB., (1999): 201(1-2):131-40.PMID: 10630632.
131.
Kameoka Sei, Leavitt P, Chang C, and Kuo SM
“Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids.” Cancer Letters, (1999): 146(2):161-7.
PMID: 10656621.
132.
Yeh S, Kang H, Miyamoto H, Nishimura K, Chang H, Fujimoto N, Ting H, Mizokami A,
Huang K, and Chang C
“Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate DU145 cells.” Endocrine, (1999):
11(2):195-202. PMID: 10709768.
133.
Chang HC, Miyamoto H, Yeh S, Lardy H, and Chang C “Suppression of Delta5-
Androstenediol-induced AR transactivation by selective steroids in human prostate cancer cells.” Proc. Natl. Acad. Sci., (1999): 96(20):11173-7.PMID: 10500149.
134.
Pan H, Uno H, Obana N, and Chang C “The roles of testosterone in the growth of keratinocytes through bald frontal dermal papilla cells.” Endocrine, (1999): 138(1):356-61.
PMID: 8977424.
135.
Liu X, Chen X, Zachar V , Chang C
, and Ebbesen P “Transcriptional activation of human
TR3/nur77 gene expression by human T-lymphotropic Virus type I Tax protein through two
AP-1-like elements.” J Gen Virol., (1999); 80 (Pt 12): 3073-81. PMID: 10567637.
136.
Miyamoto H, and Chang C “Antiandrogens fail to block completely the androstenedioneinduced mutated androgen receptor transactivation in human prostate cancer cells.”
International J. Urology, (2000): 7(1): 32-4. PMID: 10701889
25

137.
Inui S, Itami S, Pan H, and Chang C “Lack of androgen receptor transcriptional activity in human keratinocytes.” J. Dermatological Science,
(2000): 23(2): 87-92. PMID: 10808125.
138.
Nishimura K, Sampson E, Yan S, Kim E, Wang X, Uemura H, Wang C, Fujimoto N, Kang H,
Yeh S, and Chang C
“Yeast two-hybrid screening of associated proteins and characterization of mutant androgen receptors.” (2000)
: 329-343 in Yeast Hybrid Technologies (Zhu L and
Hannon G ed). Eaton Publishing.
139.
Lin D, and Chang C “Identification and characterization of an essential cis-acting element
(TR2-PACE) in the 5' promoter of human TR2 orphan nuclear receptor gene.” Endocrine,
(2000): 12(1):89-97.PMID: 10855696
140.
Hsiao P, Thin T, Lin D, and Chang C “Differential regulation of testosterone vs 5 dihydrotestosterone by selective androgen response elements.” MCB., (2000) 206(1-2):169-75.
PMID: 10839207.
141.
Wang C, Young W, and Chang C “Isolation and characterization of androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide.” Endocrine, (2000):
12(1):69-76. PMID: 10855693.
142.
Lee DK, Duan HO and Chang C “From androgen receptor to the general transcription factor
TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator.” J. Biol. Chem., (2000): 275(13):9308-13.PMID: 10734072
143.
Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou
J and Chang C “Polymorphic CAG/CAA repeat length in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.” Cancer Research, (2000):
11(4):337-41.PMID: 11927493
144.
Yeh S, Hu Y, Rahman M, Lin H, Ting H, Kang H, and Chang C “Increase of androgeninduced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.”
Proc. Natl. Acad. Sci., (2000):97, 11256-61, PMID: 11016951.
145.
Yeh S, Sampson E, Lee DK, Kim E, Hsu C, Chen Y, Chang HC, Altuwaijri S, Huang K, and
Chang C “Functional analysis of N-terminal and Ligand-binding domain of androgen receptor coactivators in prostate cancer.” J. Formosan Medical Association, (2000): 99(12):885-
94.PMID: 11155740.
146.
van Schaick HS, Rosmalen JG, Lopes da Silva S, Chang C, Burbach JP. “Expression of the orphan receptor TR4 during brain development of the rat.” Brain Res. Mol. Brain Res.,
(2000);77(1):104-10. PMID: 10814836.
147.
Mu X, Liu Y, Collins L, Kim E, and Chang C “The p53/Rb-mediated repression of testicular orphan receptor-2 in the rhesus monkey with cryptorchidism.” J. Biol. Chem., (2000):
275(31):23877-83. PMID: 10811662.
26

148.
Kinoshita H, Shi Y, Sandefur C, Meisner L, Chang C , Choon A, Reznikoff C, Bova S, Friedel
A, and Jarrard D “Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.” Cancer Research, (2000):60(13):3623-30.PMID:
10910077.
149.
Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, and Chang C “From TGF-β signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.” Proc. Natl. Acad. Sci., (2001):98, 3018-23, PMID: 11248024
150.
Lee DK, Duan HO, and Chang C “Androgen receptor interacts with the positive elongation factor P-TEF b and enhances the efficiency of transcriptional elongation.” J. Biol. Chem (2001):
276(13):9978-84. PMID: 11266437.
151.
Lin H, Yeh S, Kang H, and Chang C “Akt suppresses androgen-induced apoptosis by phosphorylatiing and inhibiting androgen receptor.” Proc. Natl. Acad. Sci., (2001):98, 7200-5.
PMID: 11404460
152.
Heinlein CA and Chang C “The role of chaperones in the nuclear translocation and transactivation of steroid receptors.” Endocrine, (2001):14(2), 143-9. PMID: 11394630.
153.
Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Messing E, Chang C, and Wu D
“Localization of androgen receptor expression in human bone marrow.” J. Pathology, (2001):
193(3):361-6. PMID: 11241417.
154.
Si ML, AI-Sharafi B, Lai C, Khardori R, Chang C , and Su CY. “Gender difference in cytoprotection induced by estrogen on female and male bovine aortic endothelial cells.”
Endocrine, (2001): 15(3): 255-62. PMID: 11762696.
155.
Sampson E, Yeh S, Chang H, Tsai M, Wang X, Ting H-J, and Chang C “Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.” J.
Biological Regulation & Homeostatic Agents, (2001): 15(2):123-9. PMID: 11501969
156.
Collins L, Lin D, Mu X, and Chang C “Feedback regulation between orphan nuclear receptor
TR2 and human papilloma virus type 16.” J. Biol. Chem., (2001): 276(29):27316-21. PMID:
11358973.
157.
Lee HJ, Lee YF, and Chang C “TR4 orphan receptor represses the human steroid 21hydroxylase gene expression through the monomeric AGGTCA motif.” Biochem. Biophys.
Res. Commun., (2001):285(5), 1361-8. PMID: 11478808.
158.
Wang X, Yeh S, Wu G, Hsu C, Wang L, Chiang T, Yang Y, Guo F, and Chang C “Cloning and characterization of androgen receptor coregulator, ARA267J.
Biol. Chem., (2001): 276(44):40417-23. PMID: 11509567.
159.
Kuo SM, Huang CT, Blum PB, and Chang C “Quercetin cumulatively enhances copper induction of metallothionein in intestinal cells.” Bio. Trace Element Res. (2001):84(1-3), 1-10.
PMID: 11817679
27

160.
Inui S, Nakajima T, Fukuzato Y, Fujimoto N, Chang C , Yoshikawa K, Itami S “Potential antiandrogenic activity of roxithromycin in skin. ”J, Dermatol Sci., (2001): 27(2):147-51. PMID:
11532379.
161.
Heinlein C and Chang C “Structural and Functional Analysis of the Androgen Receptor.” pp17-56 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical
Application. (Chang C ed). (2002):Kluwer, USA.
162.
Li M, Richter F, Chang C , Irwin RJ and Huang H. “Androgen and retinoic acid interaction in
LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor.” BMC Cancer, (2002):2;16-23. PMID: 12069693.
163.
Miyamoto H, Rahman M, Takatera H, Kang H, Yeh S, Chang H, Nishimura K, Fujimoto N, and Chang C “A dominant-negative mutant of androgen receptor coregulator, ARA54 inhibits androgen receptor-mediated prostate cancer growth.” J. Biol. Chem., (2002):277, 4609-17.
PMID: 11673464.
164.
Heinlein C and Chang C “Signal Transduction Pathways Modulate Androgen Receptor
Transcriptional Activity.” pp 57-90 in Androgens and Androgen Receptor: Mechanisms,
Functions and Clinical Application., (Chang C ed). (2002): Kluwer, USA.
165.
Schinner S, Dellas C, Schroder M, Heinlein C, Chang C
, Fischer J and Knepel W “Repression of glucagon gene transcription by PPAR

through inhibition of Pax6 transcriptional activity.” J.
Biol. Chem., (2002):277(3), 1941-8. PMID: 11707457.
166.
Shyr C, Hu YC, Kim ES, and Chang C “Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in breast cancer MCF-7 cells.” J. Biol. Chem.,
(2002):277, 14622-8. PMID: 11844790.
167.
Heinlein C, Sampson E and Chang C “Androgen Receptor Interacting Proteins Co-Activators and Co-Repressors.” pp 91-138 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application., (Chang C ed). (2002):Kluwer, USA.
168.
Ting H, Yeh S, Nishimura K, and Chang C
“Supervillin associated with androgen receptor and modulates its transcriptional activity.” Proc Natl. Acad. Sci., (2002):99, 661-6. PMID:1172840.
169.
Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA,
Mostofi FK, Chiang T, Chen YL, Stanczyk FZ and Chang C
. “Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study..” Cancer Epidemiol Biomarkers Prev., (2002):11(4);337-41.PMID: 11927493
170.
Shyr C, Collins L, Mu XM, Platt KA and Chang C “Spermatogenesis and testes development are normal in mice lacking the testicular orphan nuclear receptor-2 (TR2).” MCB., (2002):22,
4661-6. PMID: 12052874.
171.
Heinlein C and Chang C
“Nongenomic Androgen Action.” 139-154 in Androgens and
Androgen Receptor: Mechanisms, Functions and Clinical Application., (Chang C ed). (2002):
Kluwer, USA.
28

172.
Wang X, Yang Y, Guo X, Sampson E, Hsu CL, Tsai MY, Wu G, Guo Y and Chang C
“Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator.” J. Biol. Chem., (2002):277, 15426-31. PMID:11856738
173.
Heinlein CA and Chang C “Androgen receptor coregulator: an overview.” Endocrine Review,
(2002):23(2), 175-200. PMID: 11943742
174.
Lin HK, Wang L, Hu YC, Altuwaijri S and Chang C “Phosphorylation-dependent ubiquitination and degradation of AR by Akt requires Mdm2 E3 ligase.” EMBO., (2002): 21,
1-12. PMID:12145204.
175.
Fu M, Wang C, Wang J, Zhang X, sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua S,
Jaffray E, Hay RT, palvino JJ, Janne OA and Pestell R “Androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and transrepression function.” MCB., (2002):22(10), 3373-88. PMID: 11971970.
176.
Thin TH, Kim E, Yeh S, Sampson ER, Chen YT, Collin L, Basavappa R, and Chang C
“Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17 
estradiol-induced androgen receptor transactivation.” J. Biol. Chem., (2002):277(39):36499-
508. PMID:12068007.
177.
Hsing A, Culig Z, Wang X, Uemura H and Chang C “The Expanded Poly-Q Length Within
AR and AR Coregulator A1B1 And Their Clinical Implications.” pp 245-264 in Androgens and
Androgen Receptor: Mechanisms, Functions and Clinical Application., (Chang C ed).
(2002):Kluwer, USA.
178.
Hu YC, Shyr CR, Che S, Mu XM, Kim E and Chang C “Suppression of estrogen receptormediated transcription and cell growth by interaction with TR2 orphan receptor.” J. Biol.
Chem., (2002):277(37), 33571-9. PMID: 12093804.
179.
Collins L and Chang C
“Androgens in Spermatogenesis and Contraception.” pp 299-324 in
Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application., (Chang
C ed). (2002) : Kluwer, USA.
180.
Lee YF, Lee HJ and Chang C “Recent advances in the TR2 and TR4 orphan receptors of nuclear receptor superfamily.” JSBMB., (2002): 81(4-5):291-308. PMID: 12361719.
181.
Sampson E, Yeh S. Miyamoto H, Lee DK, Tsi, MY, Wang X, Hsu CL, and Chang C
“Interaction of cell cycle regulatory proteins with the androgen receptor.” pp 223-238 in
Steroid hormones and cell cycle regulation., (Burnstein KL ed). (2002):Kluwer, USA.
182.
Lin HK, Hu YC, Altuwaijri S and Chang C “Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells.” J. Biol. Chem., (2002):277, 36570-6.
PMID:12119296.
29

183.
Lee Y, Lin W, Huang J, Messing E, C Kuo, Wilding G, and Chang C “Activation of MAP kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor negative prostate cancer cells.” Cancer Research, (2002):62, 6039-44. PMID: 12414626.
184.
Itami S. Inui S, Uno H, Pan H, Chang E, Takayasu S, Ye F, Imamura K, Seki T, Ideta R, Aoki
H, Adachi K, Price V, Kurata S, Collins L, Heinlein C and Chang C “ Androgens in
Dermatology: Hair Loss, Acne, and Other Diseases.” pp 411-476 in Androgens and Androgen
Receptor: Mechanisms, Functions and Clinical Application., (Chang C ed). (2002) : Kluwer,
USA.
185.
Heinlein CA, and Chang C “The roles of AR and androgen binding proteins in nongenomic androgen actions.” Mol. Endo., (2002):16(10), 2181-7. PMID: 12351684.
186.
Yeh S, Tsai MY, Xu Q, Mu X, Lardy H, Huang KE, Lin H, Yeh SD, Altuwaijrl S, Zhou X,
Xing L, Boyce B, Hung MC, Zhang S, Gan L and Chang C “Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues.” Proc Natl. Acad. Sci., (2002): 99,13498-503. PMID: 12370412.
187.
Ohtsu H, Ishida J, Nagai M, Wang H, Itokawa H, Su C, Shih C, Chiang T, Chang E, Lee Y,
Tsai M, Chang C and Lee K “Antitumor agents 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents.” J. of Medicinal Chemistry,
(2002):45(23), 5037-42. PMID: 12408714.
188.
Shih C, Chang E, Zhang Y, Lai C, Su C, Chen Y, Chang H, Chiang T and Chang C “The use of a flow cytometry analysis in the study of different expression of androgen receptor in human prostate cancer LNCaP and PC-3 cells.” New Taipei Journal of Medicine, (2002):4, 151-8.
PMID: none.
189.
Kang H, Huang KE, Chang S, Ma WL, Lin WJ and Chang C “Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4." J. Biol.
Chem., (2002): 277, 43749-56. PMID: 12226080.
190.
Lin J, Li J, Lee YF, Yeh SD, Altuwaijri S, Ou JH and Chang C “Suppression of hepatitis B virus core promoter by the nuclear orphan receptor TR4.” J. Biol. Chem., (2003):278, 9353-60.
PMID:12522137
191.
Yang Y, Wang X, Dong T, Kim E, Lin WJ and Chang C “Identification of a novel TR4 orphan receptor associated protein (TRA16) as repressor for the selective suppression of TR4mediated transactivation.” J. Biol. Chem., (2003):278, 7709-17. PMID:12486131
192.
Lee DK and Chang C “Molecular communication between androgen receptor and general transcription machinery.” JSBMB, (2003):84(1), 41-9. PMID: 12648523.
193.
Thin TH, Wang L, Kim E, Collins LL, Basavappa R and Chang C “Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to the 17-beta estradiol treatment.” J. Biol. Chem., (2003): 278(9):7699-708. PMID: 12499384.
30

194.
Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S and Chang C “Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator
ARA70 mutant in prostate cancer cells.” J. Biol. Chem., (2003): 278(22),19619-26. PMID:
12649293.
195.
Rahman MM, Miyamoto H, Lardy H and Chang C “Inactivation of androgen receptor (AR) coregulator ARA55 leads to an inhibition of AR transactivation and a reduction of the agonist activity of antiandrogens in prostate cancer cells." Proc Natl. Acad. Sci., (2003):100(9), 5124-
9. PMID: 12700349.
196.
Lee DK, Li M and Chang C “The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor.” BBRC., (2003): 302(1), 162-9. PMID:
12593864.
197.
Miyamoto H, Marwah P, Lardy H and Chang C
"3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity." Proc Natl. Acad. Sci.,
(2003):100, 4440-4444. PMID: 12672951.
198.
Yang L, Lin HK, Altuwaijri S, Xie S and Chang C “APPL suppresses androgen receptor transactivation via potentiating Akt activity.” J. Biol. Chem., (2003):278(19), 16820-7.
PMID:12621049.
199.
Hsu CL, Yeh S, Chen YL, Ting HJ, Hu YC, Hank L, Wang X and Chang C “The use of phase display technique for the isolation of androgen receptor interacting peptides with F/WXXLF/W and FXXLY new signature motifs.” J. Biol. Chem., (2003):278, 23691-23698.
PMID:12714604.
200.
Mu X, and Chang C.
“TR3 orphan nuclear receptor mediates apoptosis through up-regulating
E2F1 in human prostate cancer LNCaP cells” J. Biol. Chem.k (2003):278(44), 42840-45.
PMID: 12947120.
201.
Kim E, Xie S, Lee YF, Collins L, Hu YC, Shyr CR, Mu XM, Liu NC, Chen YT, Wang PH, and
Chang C “ApoE-TR4 orphan nuclear receptor induces the expression of liver apolipoprotein
E/C-I/C-II gene cluster via hepatic control region.” J. Biol. Chem., (2003):278, 46919-46926.
PMID: 12954636.
202.
Lee HJ, Sampson ER, Hsu CL, Chen YT and Chang C “Androgen receptor.” pp 87-101 in
Molecular mechanisms of action of steroid receptors (Marija and Costas Demonacos ed). (2003)
Research Signpost, India.
203.
Chey WY, Chang CH, Pan H, Chang C
, Kim BK, Park IS and Chang TM “Evidence on the presence of secretin cells in the gastric antral and oxyntic mucosa.” Regulatory Peptides,
(2003):111(1-3), 183-90. PMID: 12609767.
204.
Yang L, Wang L, Lin HK, Kan P, Xie S, Tsai MY, Wang PH, Chen YT and Chang C
“Interleukin-6 differentially regulates androgen receptor transavtivation via PI3K-Akt, STAT3
31

and MAPK three distinct signal pathways in prostate cancer cells.” BBRC., (2003):305(3),
462-9. PMID: 12763015.
205.
Lee H, and Chang C
“Recent advances in the androgen receptor action.” Cellular and
Molecular Life Sciences., (2003):60(8), 1613-22. PMID: 14504652.
206.
Inui S, Lee YF, Chang E, Shyr CR and Chang C
“Differential and bidirectional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor

(PPAR
 ) in human HaCaT keratinocytes.” J. of Dermatology
Science, (2003) : 31(1):65-71. PMID: 12615366.
207.
Mu X and Chang C “TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.” The Prostate, (2003):57(2), 129-33. PMID: 12949936.
208.
Heinlein CA, and Chang C “Induction and Repression of Peroxisome Proliferator-Activated
Receptor alpha (PPAR

) Transcription by the Coregulator ARA70.” Endocrine, (2003):21(2),
139-46. PMID: 12897377.
209.
Cai Y, Dai T, Ao Y, Konishi T, Chuang KH, Lue Y, Chang C and Wan Y “Cytochrome P450 genes are differentially expressed in female and male hepatocyte retinoid X receptor a-deficient mice.” Endocrinology, (2003):144(6), 2311-8. PMID: 12746291.
210.
Kang HY, Tsai MY, Chang C and Huang KE “Mechanisms and clinical relevance of androgens and androgen receptor action.” Chang Gung Medical J., (2003):26(6), 388-402.
PMID: 12956285.
211.
Lee DK and Chang C “Expression and Degradation of Androgen Receptor: Mechanism and
Clinical Implication.” J Clin Endocrinol Metab., (2003):88, 4043-954. PMID: 12970260.
212.
Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S,
Shin M, AozasaK, Okuyama A and Chang C
“Modulation of androgen receptor transactivation by gelsolin: A new identified AR coregulator” Cancer Research, (2003):63, 4888-94. PMID:
12941811.
213.
Altuwaijri S, Lin HK, Chuang KH, Yeh S, Hanchett L, Zhang Y, Tsai MT, Yang L, and Chang
C “Interruption of NFkB Signaling by Androgen Receptor Facilitates TPA-induce apoptosis in an Androgen Sensitive Prostate Cancer Cell Line.” Cancer Research, (2003):63, 7106-12.
PMID: 146503.
214.
Fu M, Rao M, Wang C, Sakamaki T, Wang J, Vizio DD, Zhang X, Albanese C, Balk S, Chang
C Fan S, Rosen E, Palvimo J, Janne O, Muratoglu S, Avantaggiati ML and Pestell RG
“Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth.” MCB., (2003):23(23), 8563-73. PMID: 14612401.
215.
Yeh S, Hu YC, Wang PH, Xie C. Xu Q, Zhou X, Tsai MY, Dong Z, and Chang C “Abnormal mammary gland development and growth retardation in breast cancer MCF7 cells and female mice lacking androgen receptor.” J. Experimental Medicine, (2003): 198, 1899-908. PMID:
14676301.
32

216.
Ohtsu H, Itokawa H, Su CY, Shih C, Chiang T, Chang E, Lee YF, Chen YT, Chang C and Lee,
KH. “Antitumor Agents 222. Synthesis and Anti-androgen Activity of New Diarylheptanoids.”
Bioorg. Med. Chem., (2003):11(23), 5083-90. PMID: 14604672.
217.
Lin H, Hu W, Yang L, Altuwaijri S, Chen YT, Kang HY and Chang C “Suppression vs induction of androgen receptor by the PI3K/Akt pathway in prostate cancer LNCaP cells with different passage numbers.” J. Biol. Chem., (2003):19, 50902-7. PMID: 14555644
218.
Collins L, Lee H, Chen YT, Yeh S and Chang C "Androgen receptor in spermatogenesis.”
Cytogenetic and Genome Research,(2003):103(3-4), 289-301. PMID: 15051951.
219.
Miyamoto H, Rahman MM and Chang C
“Molecular basis for the antiandrogen withdrawal syndrome” J. Cellular Biochemistry, (2004):91(1), 3-12. PMID: 14689576.
220.
Wang PH and Chang C "Androgens and ovarian cancers” Eur. J. Gynaec. Oncol.,
(2004):25(2), 157-63. PMID: 15032272.
221.
Zhang Y, Yang Y, Yeh S and Chang C “ARA67 functions as a repressor to suppress androgen receptor transactivation.” MCB., (2004):24, 1044-57. PMID: 14729952.
222.
Hu YC, Wang PH, Hu YC, Yeh S, Xie C, Zhou X, Xu Q, Chao HT, Tsai MY, and Chang .
“Subfertility and defective folliculogenesis in female mice lacking androgen receptor.” Proc
Natl. Acad. Sci., (2004):101, 11209-14. PMID: 15277682.
223.
Yang L, Yeh SD, Xie S, Altuwaijri S, Ni J, Hu YC, Chen YT, Bao BY, Su CH and Chang C
“Androgen suppresses PML protein expression in prostate cancer CWR22R cells” BBRC.,
(2004):314(1), 69-75. PMID: 14715247.
224.
Heinlein CA and Chang C “Androgen receptor in prostate cancer.” Endocrine Reviews,
(2004):25, 276-308. PMID: 15082523.
225.
Rahman M, Miyamoto H, and Chang C “Androgen Receptor Coregulators in Prostate Cancer
Progression: Mechanisms and Clinical Implications.” Clinical Cancer Research, (2004):10(7),
2208-19. PMID: 15073094.
226.
Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Ken P and Chang C “Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells” MCB., (2004):24, 2202-13. PMID: 14966297.
227.
Litvinov I, Chang C and
Isaacs J. “Molecular characterization of commonly-used human androgen receptor expression vector, pSG5-AR” The Prostate, (2004):58(4), 319-24. PMID:
14968432.
228.
Miyamoto H, Messing E and Chang C “Androgen Deprivation Therapy for Prostate Cancer:
Current Status and Future Prospects.” The Prostate, (2004):61(4), 332-53. PMID: 15389811.
33

229.
Chang C, Chen YT, Yeh SD, Xu Q, Guillou F, and Yeh S “Infertility with defective spermatogenesis and hypotestosteronemia in mice lacking androgen receptor in Sertoli cells.”
Proc Natl. Acad. Sci. (2004):101(18), 6876-81. PMID: 15107499.
230.
Xie S, Lin HK, Ni J, Wang L, Yang L, di Sant’Agnese PA, and
Chang C “Regulation of interleukin-6 mediated P13K activation and neurendocrine diffrentiation by androgen signaling in prostate cancer LNCaP cells.” The Prostate, (2004):60(1), 61-7. PMID: 15129430.
231.
Mu X, Liu NC, Chen YT, Collins L, Kim E, Shyr CR, Lee YF and Chang C “Target inactivation of TR4 orphan receptor delays and disrupts late meiotic prophase and subsequent meiotic divisions of spermatogenesis” MCB., (2004):24, 5887-99. PMID: 15199144.
232.
Wang L, Lin HK, Hu YC, Mu X, Xie S, and Chang C “Glycogen Synthatase Kinase 3

Negatively Regulates Androgen Receptor-Dependent Transcription and Cell Growth.” JBC.,
(2004):279, 32444-52. PMID: 15178691.
233.
Lin H, Hu W, Lee K and Chang C “Regulation of androgen receptor signaling by PTEN
(phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.” Mol.Endo., (2004):18, 2409-23. PMID:
15205473.
234.
Hu YC, Yeh S, Yeh SD, Sampson E, Li P, Hsu CL, Ting H, Lin H, Wang L, Kim E and Chang
C “Functional Domain and Motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.” JBC., (2004):279, 33438-46. PMID:15166229.
235.
Ting HJ, Hu YC, and Chang C “Actin monomer enhances supervillin-modulated androgen receptor transactivation.” BBRC., (2004):319(2), 393-6. PMID: 15178419.
236.
Kang HY, Cho CL, Wang JC, Hu YC, Lin HK, Chang C (corresponding author) and Huang KE
“Nongenomic Androgen Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in
MC3T3-E1 Osteoblasts.” JBMR., (2004):19(7), 1181-90. PMID: 15177002.
237.
Collins L, Lee YF, Lin WJ, Heinlein CA, Liu NC, Chen YT, Chen Y, Shyr CR, Meshul CK,
Uno H, Chou S, Platt KA and Chang C
“Growth retardation and abnormal female maternity in mice lacking testicular orphan nuclear receptor 4.” PNAS., (2004):101. 15058-63. PMID:
15477591.
238.
Altuwaijri S, Lee DK, Chuang KH, Ting HJ, Yang Z, Xu Q, Tsai MY, Yeh S, Hanchett LA,
Chang HC and Chang C “Androgen receptor regulates expression of skeletal muscle specific proteins and muscle cell types.” Endocrine, (2004):25(1), 27-32. PMID: 15545703.
239.
Lee YF, Bao BY and Chang C “Modulation of the retinoic acid-induced cell apoptosis and differentiation by the human TR4 orphan receptor.” BBRC. (2004):323(3), 876-83. PMID:
15381082.
240.
Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S,
Pimplikar SW, Chang C
. “Androgen receptor (AR) NH2- and COOH-terminal interactions
34

result in the differential influences on the AR-mediated transactivation and cell growth”. Mol
Endo., (2005):19(2):350-61. PMID: 15514032.
241.
Wang l, Hsu CL and Chang C “Androgen receptor corepressors: an overview.” The Prostate,
(2005):63(2), 117-30. PMID: 15486994.
242.
Miyamoto H and Chang C
“Hormonal therapy for prostate cancer: clinical and experimental evidence.” pp 1-32. in Prostate Cancer: Basic Mechanisms and Therapeutic Approaches,
(Chang C ed). (2005): World Scientific. USA.
243.
Kim E, Yang Z, Liu B and Chang C “Induction of apolipoprotein E expression by TR4 orphan nuclear receptor via 5' proximal promoter region.” BBRC., (2005):328(1), 85-90. PMID:
15670754.
244.
Chen YT, Collins LL, Uno H and Chang C “Deficits in Motor coordination with Aberrant
Cerebellar Development in Mice Lacking Testicular Orphan Nuclear Receptor 4.” MCB.,
(2005):25, 2722-32. PMID: 15767677.
245.
Lin H, Xu Q, Yeh S, Wang RS, Sparks JD and Chang C “Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor.” Diabetis, (2005):54, 1717-25.
PMID:
15919793.
246.
Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang
KH, Wu CT, Chang C "Induction of Androgen Receptor Expression by Phosphatidylinositol
3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP
Prostate Cancer Cells." JBC., (2005):280(39):33558-65. PMID: 16061480.
247.
Chuang KH, Lee YF, Lin WJ, Chu CY, Altuwaijri S, Wan YY and Chang C "9-Cis-Retinoic
Acid Inhibits Androgen Receptor Activity Through Activation of Retinoid X Receptor." Mol.
Endo., (2005):19(5):1200-12. PMID: 15650026.
248.
Wu C, Yeh S, Xu Q, Yang Z, Chang P, Yu Y, and Chang C
“Study of androgen receptor roles in prostate cancer using mice lacking functional prostate androgen receptor” pp 223-238 in
Prostate Cancer: Basic Mechanisms and Therapeutic Approaches, (Chang C ed). (2005) : World
Scientific. USA.
249.
Miyamoto H, messing E and Chang C “Does androgen deprivation therapy improve treatment outcomes in patients with low- and intermediate-risk prostate cancer” Nature Clinical Practice:
Oncology, (2005):2. 236-7. PMID: 16264955.
250.
Miyamoto H, Altuwaijri S, Cai Y, Messing E and Chang C "Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer." Mol. Carcinogen,
(2005):44(1):1-10. PMID: 16044418.
251.
Fujimoto N, Chang C, Nomura M and Matsumoto T "Can we prevent prostate cancer?
Rationale and current status of prostate cancer chemoprevention." Urol. Int., (2005):74(4), 289-
97. PMID: 15897691.
35

252.
Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY , Altuwaijri1 S, Chang C and Henry
Lardy “Identification of steroid derivatives that function as potent antiandrogens” Int. J. Cancer,
(2005):117(5), 866–72. PMID: 15981214.
253.
Mu X, Yang L, and Chang C "Stage dependent and androgen inductive expression of orphan receptor TR4 in rat testis." BBRC., (2006):341(2), 464-9. PMID: 16414012.
254.
Marwah P, Marwah A, Lardy H, Miyamoto H and Chang C "C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists" Bioorganic & Medical Chemistry, (2006):14(17). 5933-47.
PMID: 16759873.
255.
Wang RS, Yeh S, Chen LM, Lin HY, Zhang C, Ni J, Wu CC, di Sant'agnese PA, de Mesy-
Bentley KL, Tzeng CR, and Chang C
” Androgen Receptor in Sertoli Cell Is Essential For
Germ Cell Nursery and Junctional Complex Formation in Mouse Testes” Endocrinology,
(2006):147(12):5624–33. PMID: 16973730.
256.
Tsai MY, Yeh SD, Wang RS, Yeh S, Zhang C, Lin HY, Tseng CR and Chang C “Differential
Effects of Spermatogenesis and Fertility in Mice Lacking Androgen Receptor in Individual
Testis Cells” PNAS., (2006):103(50):18975-80.
PMID: 17142319.
257.
Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY, Wang RS, Chang YJ, Mendis C, Hu
L, Lardy H and Chang C “Oligozoospermia with Normal Fertility in Male Mice Lacking the
Androgen Receptor in Testis Peritubular Myoid Cells” PNAS., (2006):103(47):17718-23.
PMID: 17095600
258.
Wang CP, Lee YF, Chang C and Lee HJ “Transactivation of the proximal promoter of human oxytocin gene by TR4 orphan receptor” BBRC., (2006):351(1), 204–208. PMID: 17054912.
259.
Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, Sant’Agnese A and
Chang C “Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth” Mol. Endo., (2006):21(2):343-58.
PMID:17082327
260.
Yang Z, Chang YJ, Miyamoto H, Yeh S, Yao YL, di Sant’Agnese PA, Tsai MY, and Chang C
“Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonuleoprotein A1 via interaction with AR coregulator ARA54”
Endocrinology, (2006):148(3):1340-9. PMID: 17227886.
261.
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Hu YC, Tsai MY, Yeh S,
Messing E and Chang C “Promotion of Bladder Cancer Development and Progression by
Androgen Receptor Signals” JNCI.,(2007):99: 558 – 68. PMID: 17406000
262.
Yang Z, Chang YJ, Yu IC, Miyamoto H, Wu CC, Yeh S, Merry DE, Sobue G, Chen LM and
Chang C “ASC-J9 ameliorates spinal and bulbar muscular atrophyphenotype via degradation of androgen receptor” Nature Medicine, (2007):13(3): 348 – 53. PMID: 17334372.
36

263.
Zhang Y, Chen YT, Xie S, Wang L, Lee YF, Chang SS and Chang C “ Loss of Testicular
Orphan Receptor 4 Impairs Normal Myelination in Mouse Forebrain” Mol. Endo.,
(2007):21(4):908–20. PMID: 17227886.
264.
Altuwaijri S, Wu CC, Niu Y, Chang HC, and Chang C “Expression of human AR cDNA driven by its own promoter results in mild promotion but not suppression of growth in human prostate cancer PC-3 cells.” AJA., (2007):9 (2): 181–8. PMID: 17334587.
265.
Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X, Campbell AD, Chen YT,
Chang C
, Yamamoto M, Tanimoto K, Engel JD.“Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4” EMBO., (2007):2; 26(9):2295-306.
PMID: 17431400.
266.
Zheng Y, Chen Kl, Ma WL , Chang C
, Ou JH “Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein.” Virology, (2007): 5;363(2):454-61. PMID:
17335866.
267.
Yu SF, Cheng TT, Hsu YH, Lai HM, Chen YC, Chiu CK, Lin KM, Chang C , Chen CJ, Kang
HY. “Association of tri-nucleotide (CAG and GGC) repeat polymorphism of androgen receptor gene in Taiwanese women with refractory or remission rheumatoid arthritis.” Clin. Rheumatol.,
(2007):26(12):2051-8. PMID: 17431729.
268.
Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY , and Chang C
“Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor” PNAS., (2007):104(31):12679–84. PMID: 17652515.
269.
Chen YT, Collins LL, Uno H, Chou SM, Meshulf CK, Chang SS and Chang C "Abnormal cerebellar cytoarchitecture and impaired inhibitory signaling in adult mice lacking TR4 orphan nuclear receptor" Brain Research, (2007):1168:72-82. PMID: 2084075.
270.
Chen YT, Collins LL, Chang SS and Chang C “The roles of testicular orphan nuclear receptor 4 (TR4) in cerebellar development”. Cerebellum, (2008); 7(1):9-17. PMID: 18418664
271.
Kim E, Ma WL, Lin DL, Inui S, Chen YL, and Chang C “TR4 orphan nuclear receptor functions as an apoptosis modulator via regulation of Bcl-2 gene expression”. BBRC.,
(2007):361(2):323-8. PMID: 17655826.
272.
Xu Q, Lin HY, Yeh SD, Yu IC, Wang RS, Chen YT, Zhang C, Altuwaijri S, Chen LM, Chuang
KH, Chiang HS, Yeh S and Chang C . “Infertility with defective spermatogenesis and steroidogenesis in male mice lacking androgen receptor in Leydig cells.” Endocrine, (2007):
32(1):96-106. PMID: 17955388.
273.
Liu NC, Lin WJ, Kim E, Collins LL, Lin HY, Yu IC, Sparks JD, Chen LM, Lee YF and Chang
C “Loss of TR4 Orphan Nuclear Receptor Reduces Phosphoenolpyruvate Carboxykinase-
Mediated Gluconeogenesis” Diabetes, (2007):56:2901-9. PMID: 17827404.
37

274.
Hamalainen-Laanaya HK, Kobie JJ, Chang C and Zheng W “Temporal and Spatial Changes of
Histone 3 K4 Dimethylation at the IFN-Gene during Th1 and Th2 Cell Differentiation” J. of
Immunology, (2007):179(10):6410-5. PMID: 17982028.
275.
Zhao X, Zheng B, Huang Y, Yang D, Katzman S, Chang C , Fowell D and Zheng W
“Interaction between GATA-3 and the Transcriptional Coregulator Pias1 Is Important for the
Regulation of Th2 Immune Responses” J. of Immunology, (2007):179(12):8297–304. PMID:
18056374.
276.
Miyamoto H, Altuwaijri S and Chang C “Androgen Receptor in Prostate Cancer” Prostate
Cancer: Signaling Networks, Genetics, and New Treatment Strategies, (Pestell R and
Nevalainen ed) (2008):pp 129-146.
277.
Chen LM, Wang RS, Lee YF, Liu NC, Chang YJ, Wu CC, Xie S, Hung YC and Chang C .
“Subfertility with Defective Folliculogenesis in Female Mice Lacking TR4 Orphan Nuclear
Receptor” Mol. Endo., (2008):22(4):858-67. PMID: 1874360.
278.
Yu IC, Lin HY, Liu NC, Wang RS, Sparks JD, Yeh S and Chang C
. “Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue.” Endocrinology. (2008):
47(6):1924-35. PMID: 18449947.
279.
Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL and Chang C.
“A new prostate cancer therapeutic approach: Combination of androgen ablation with COX-2 inhibitor” Int. J. Cancer,
(2008):123(1), 195–201. PMID: 18386814.
280.
Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks
JD, Yeh S and Chang C “Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor” Hepatology, (2008):47(6):1924-35. PMID: 18449947.
281.
Li G, Lee YF, Liu S, Cai Y, Xie S, Liu NC, Bao BY, Chen Z and Chang C
. “Oxidative Stress
Stimulates TR4 Orphan Receptor through Forkhead Transcription Factor FOXO3a”
Endocrinology, (2008):149(7):3490-9. PMID: 18388194.
282.
Ting HJ and Chang C “Actin Associated Proteins Function as Androgen Receptor
Coregulators: An Implication of Androgen Receptor's Roles in Skeletal Muscle” The Journal of
Steroid Biochemistry and Molecular Biology. (2008):111(3-5):157-63. PMID: 18590822
283.
Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC and Chang C
“Tissue prostate specific antigen (PSA) facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation” Cancer Research, (2008):68:
(17), 7110-19. PMID: 1857426. PMC2587124. NIHMSID # 58471.
284.
Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S and Chang C
“Androgen receptor is a tumor suppressor and proliferator in prostate cancer”, PNAS.,
(2008):105(34):12182-7. PMID: 18723679. PMC2527886.
38

285.
Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H and Chang C
“Targeting the stromal androgen receptor in primary prostate tumors at earlier stages” PNAS.,
(2008):105(34):12188-93. PMID: 18723670. PMC2527887.
286.
Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S and Chang C
“New therapeutic target for Hepatocellular Carcinoma: Lessons from Androgen Receptor
Knockout mice model in Hepatocarcinogenesis”, Gastroenterology, (2008):135(3):947-55.
PMID: 18639661.
NIHMS#69375.
287.
Kang HY, Shyr CR, Huang CK, Tsai MY, Orimo H, Lin PC, Chang C (co-corresponding author) and Huang KE “Altered TNSALP expression and phosphate regulation contribute to reduced mineralization in mice lacking androgen receptor” MCB. (2008): 28(24): 7354-67. PMID:
18838539.
288.
Yu S, Lai KP, Xie S, Chang HC, Chang C (co-corresponding author) and Yeh
S. “The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer” Asia Journal Andrology, (2008): 11(1):39-48.PMID: 19098932
289.
Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, Chang C , Messing EM and Yeh S.
“Defects of Prostate Development and Reproductive System in the ER{alpha} Null Male
Mice.” Endocrinology,
(2009): 150(1): 251-9, PMID: 18755802.
290.
Chen M, Wolfe A, Wang X, Chang C , Yeh S, Radovick S. “Generation and characterization of a complete null estrogen receptor alpha mouse using Cre/LoxP technology.” MCB. (2009).
321(1-2):145-53, PMID: 18953638.
291.
Altuwaijri S, Chuang KH, Lai KP, Lai JJ, Lin HY, Young FM, Bottaro A, Tsai MY, Yeh S and
Chang C “Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells” Mol. Endo., (2009); 23(4):444-53. PMID: 19164450
292.
Wang RS, Yeh S, Tzeng CR, and Chang C “Androgen Receptor Roles in Spermatogenesis and
Fertility: Lessons from Testicular Cell-Specific Androgen Receptor Knockout Mice” Endocrine
Review,
(2009); 30(2): 119-32. PMID: 19176467
.
293.
Shyr CR, Kang HY, Tsai MY, Liu NC, Ku PY, Huang KE and Chang C. “ Roles of testicular orphan nuclear receptors 2 and 4 in early embryonic development and embryonic stem cells’
Endocrinology (
2009) 150(5): 2454-2462. PMID: 19131575.
294.
Chuang KH, Altuwaijri S, Li G, Lai JJ, Chu CY, Lin YH, Lai KP, Hsu JW, Kang P, Wu MC, and Chang C “Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor” JEM, (2009);206(5):1181-99. PMID: 19414555.
295.
Kang HY, Huang HY, Hsieh CY, Li CF, Shyr CR, Tsai MY, Chang C , Chuang YC, Huang
KE “ Activin A Enhances Prostate Cancer Cell Migration via Activation of Androgen Receptor and Is Overexpressed in Metastatic Prostate Cancer”
JBMR. (2009) 24(7):1180-93. PMID:
19257827.
39

296.
Yeh S, Niu Y, Miyamoto H, Chang T and Chang C (2009) “ Differential Roles of Androgen
Receptor in Prostate Development and Cancer Progression ” pp 73-89 in Androgen Action in
Prostate Cancer
, (Tindall D and Mohler J ed) : World Scientific. USA.
297.
Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG,
Chang C , Scher HI, Gerald WL “NF-{kappa}B Regulates Androgen Receptor Expression and
Prostate Cancer Growth” Am J Pathol.(2009); PMID: 19628766.
298.
Liu NC, Lin WJ, Yu IC, Lin HY, Liu S, Lee YF and Chang C “Activation of TR4 orphan nuclear receptor gene promoter by cAMP/PKA and C/EBP signaling” Endocrine. (2009).PMID:
19618297
299.
Xie S, Lee YF, Kim E, Chen LM, Ni J, Fang LY, Liu S, Lin SJ, Abe JI, Berk B, Ho FM and
Chang C “TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation” PNAS (2009): 106(32):13353-8.PMID: 19666541.
300.
Zeng WP, Chang C , Lai JJ “Immune Suppressive Activity and Lack of T Helper
Differentiation Are Differentially Regulated in Natural Regulatory T Cells”. J Immunol. (2009)
183: 3583–90.PMID: 19710452.
301.
Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL, Huang CC, Huang KE and Chang
C “Tumor suppressor PAX6 functions as androgen receptor Co-repressor to inhibit prostate cancer growth” Prostate. (2009). PMID: 19790232.
302.
Lee YF, Liu NC, Liu S, Wang RS, Ho HC, Yan SJ, Li G, Chen LM, Lin WJ, Puzas E and
Chang C (2007) “Premature aging like syndromes and impaired genomic stability maintenance in mice lacking TR4 orphan nuclear receptor” JEM submitted
303.
Collin L, Lee YF, Lin WJ, Heinlein CA, Liu NC, Chen YT, Shyr CR, Meshul CK, Uno H,
Chou SM, Chen YT and Chang C (2009), “Priapism, reduced fertility, and abnormal sextual behavior in male mice lacking Testicular orphan nuclear Receptor 4”, Endocrinology, submitted
304.
Wang L, Zhang Y, Xu Q, Chen M, Hu YC, Chen Y and Chang C (2007) “An Arginine/Serinerich Protein, ARA50, functions as Androgen Receptor coregulator in PC-3 Prostate Cancer
Cells.” Endocrine, Submitted
(Abstracts are also available upon request)
40